

April 21, 2026

Listing Compliance Department
National Stock Exchange of India Limited.
Exchange Plaza,
Bandra-Kurla Complex,
Bandra (E), Mumbai 400051

Listing Compliance Department
BSE Limited.
Phirozee Jeejeebhoy
Towers, Dalal Street, Fort,
Mumbai - 400 001

NSE Symbol: VIKASLIFE

Scrip Code: 542655

Sub: Outcome of Board Meeting held on Tuesday, April 21, 2026

Dear Sir/Madam,

In compliance with the provisions of Regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Board of Directors of the Company, at its meeting held today i.e. April 21, 2026, at Registered Office of the Company at Vikas House, 3, Arihant Nagar, Rohtak Road, Punjabi Bagh, Delhi 110026, inter- alia, transact the following businesses:

1. Un-audited Financial Results for the quarter and half year ended September 30, 2025

The Board approved the Un-audited Financial Results (Standalone and Consolidated) of the Company for the quarter and half year ended September 30, 2025, as reviewed and recommended by the Audit Committee. The said results were subjected to Limited Review by the Statutory Auditors of the Company. In compliance with Regulation 33 of the SEBI (LODR) Regulations, 2015, we are enclosing (a) copy of Limited Review Report along with Un-audited Financial Results (Standalone) as Annexure-I and (b) copy of Limited Review Report along with Un-audited Financial Results Consolidated) as Annexure-II.

2. Un-audited Financial Results for the quarter and nine months ended December 31, 2025

The Board approved the Un-audited Financial Results (Standalone and Consolidated) of the Company for the quarter and nine months ended December 31, 2025, as reviewed and recommended by the Audit Committee. The said results were subjected to Limited Review by the Statutory Auditors of the Company. In compliance with Regulation 33 of the SEBI (LODR) Regulations, 2015, we are enclosing (a) Limited Review Report along with Un-audited Financial Results (Standalone) as Annexure-III and (b) copy of Limited Review Report along with Un-audited Financial Results (Consolidated) as Annexure-IV.

3. Approval for seeking Members' consent through Addendum to Postal Ballot Notice

The Board approved seeking prior approval of the members, by way of an addendum to the postal ballot notice already circulated, pursuant to the applicable provisions of the Companies Act, 2013, SEBI Regulations, and other applicable laws, to enable the Company to undertake, in the ordinary course of business, certain transactions and arrangements including related party transactions, investments, loans, guarantees, provision of securities, and creation of charges/mortgages, within such limits as may be approved by the members and determined by the Board from time to time, for efficient conduct of the Company's business operations.

Regd. Office : Vikas House, 3, Arihant Nagar, Rohtak Road, Punjabi Bagh West, Delhi 110026

Factory I : G-83, Vigyan Nagar, RIICO Indl. Area, Shahjahanpur, Dist. Alwar, Rajasthan - 301706

Factory II : Plot No. 193, Revenue Survey No. 93, Baikampady, Dist. Dakshina Kannada, Mangaluru, Karnataka - 575011



Vikas Lifecare Limited

(A NSE / BSE Listed Company)

CIN : L25111DL1995PLC073719

Web : www.vikaslifecarelimited.com

Email : info@vikaslifecarelimited.com

Tel. : +91-11-40450110

The meeting of the Board of Directors commenced at 06:25 P.M. and concluded at 10:15 P.M.

We request you to kindly the information on record and oblige.

Thanking you,

Yours Faithfully,
for **Vikas Lifecare Limited**

Sundeep Kumar Dhawan
Managing Director (DIN: 09508137)





**Independent Auditor's Limited Review Report on the Quarterly and Half Yearly Unaudited Standalone Financial Results of Vikas Lifecare Limited pursuant to the Regulations 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulation 2015, as amended
Limited Review Report**

To The Board of Directors

Vikas Lifecare Limited

1. We have reviewed the accompanying statement of unaudited standalone financial results of Vikas Lifecare Limited for the quarter and half year ended 30th Sep, 2025 and being submitted by the company pursuant to requirements of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations).
2. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to express a conclusion on the statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable Ind AS 34 and other recognized accounting practices and policies generally accepted in India has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

Emphasis of Matters

5. We draw attention to Note 9 to the accompanying financial results which describes that during the previous year, Eraaya Lifecare Limited ("ELL") had acquired the Ebix Inc and its global subsidiaries pursuant to Chapter 11 proceedings under the supervision of the Dallas Court, U.S. As further detailed in the said note, Vikas Lifecare Limited ("VLL"), as part of the consortium led by ELL, had contributed INR 2,977.27 million (equivalent to US\$ 34.83 million) towards the acquisition of Ebix Inc. In terms of an addendum agreement dated August 16, 2024, VLL was entitled to receive 51% equity shares of Ebix International Holdings Limited ("EIHL"), a subsidiary of the Ebix Inc, in the event of non-repayment by ELL. Upon such non-repayment by January 31, 2025, VLL invoked the arbitration clause, and the matter was settled during the quarter ended June 30, 2025 through a settlement deed. Pursuant thereto, 51% equity shares of EIHL



have been transferred to VLL. Further, the requisite approvals, including regulatory approvals, as may be applicable for the aforesaid transaction, are in the process of being obtained by the Company. The management has represented that it is undertaking a comprehensive review of compliance requirements across jurisdictions and is actively coordinating with legal and regulatory advisors to regularize such compliances, considering the cross-border nature of the transaction

6. Restatement of unaudited standalone financial results for the quarter ended June 30, 2025

We draw attention to Note 13 to the accompanying financial results, which describes that unaudited standalone financial result for the quarter ended June 30, have been restated to reflect additional facts that came to management's attention subsequent to the issuance of the previously reported financial results. These developments relate to the transfer of shares of Ebix International Holding Limited (Ebix UK), a step down subsidiary of the Eraaya Lifespaces Limited in pursuance of settlement deed. Accordingly, the previously reported figures and disclosure in financial results have been restated to appropriately incorporate the effect and presentation in respect to such settlement.

7. Related Party Transactions

We draw attention to Note 10 to the accompanying financial results which describes which describes that during the half year ended September 30, 2025, the Company entered into certain related party transactions. As stated in the said note, in terms of Regulation 23 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, prior approval of the shareholders is required for material related party transactions; however, as at the date of approval of these financial results, such approval has not yet been obtained.

Further, the company is in the process of evaluating the regulatory compliance requirements and obtaining the necessary approvals, where applicable. Management is also reviewing the supporting documentation and underlying business rationale in respect of the aforesaid transactions and will take appropriate actions, including providing additional disclosures, if considered necessary.

8. Transaction relating to Investment in IGL Genesis Technologies Limited

We draw attention to Note 11 to the accompanying financial results, which describes that M/s Genesis Gas Solutions Private Limited ("GGPL") has entered into a Share Purchase Agreement with Vikas Lifecare Limited ("VLL") for the transfer of its investment in IGL Genesis Technologies Limited ("IGTL"), pursuant to which the shares were transferred in dematerialized form in May 2025. However, as at the reporting date and the date of approval of these financial results, certain conditions precedent to the completion of the transaction remains pending.

As further explained in the said note, the transfer is subject to requisite approvals from the Board of Indraprastha Gas Limited and the Board of IGTL, in accordance with the terms of the Shareholders' cum Joint Venture Agreement, and pending such approvals, the name of the shareholder as appearing in the register of members of IGTL continues to remain unchanged.



In view of the above, the transfer of shares has not been given effect in the books of account. The accounting treatment of the said investment will be determined upon completion of the transaction and receipt of the necessary approvals.

9. Tax Implications of Settlement Transaction

We draw attention to note 12 in the accompanying financial results, which describes that pursuant to the transaction involving contribution made by the Company towards acquisition of Ebix Inc. and subsequent settlement thereof, the Company has received 51% equity shares of Ebix UK in accordance with the Settlement Agreement dated 14 May 2025.

The Company is in the process of evaluating the tax implications arising from the aforesaid transaction, including the characterization of the transaction, its taxability under applicable laws, Pending completion of such evaluation and receipt of expert opinions, no tax impact, if any, has been recognized in the accompanying financial results.

Our conclusion is not modified in respect of above matters.

For KSMC & Associates
Chartered Accountants
FRN: 003565N

CA SACHIN SINGHAL
(Partner)

M. No: 505732

UDIN: 26505732RFFWHW4918



Place: New Delhi
Date: 21.04.2026

VIKAS LIFECARE LIMITED

CIN - L25111DL1995PLC073719

REGD OFF: VIKAS HOUSE,3,ARIHANT NAGAR ROHTAK ROAD,PUNJABI BAGH WEST,DELHI-110026 PH NO: 011-40450110 EMAIL - info@vikaslifecarelimited.com

UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED 30TH SEPTEMBER, 2025

Sr. No.	Particulars	Three Months Ended			Half Year Ended		Year Ended
		30-Sep-25	30-Jun-25	30-Sep-24	30-Sep-25	30-Sep-24	31-Mar-25
		Unaudited	Unaudited-Restated	Unaudited	Unaudited**	Unaudited	Audited
1	Revenue from Operations						
a.	Revenue from Operations	14,097.78	8,869.19	13,035.63	22,966.97	22,191.81	46,357.62
2	Other Income	68.17	13,274.67	351.40	13,342.84	590.43	2,632.65
3	Total Income (1+2)	14,165.94	22,143.86	13,387.02	36,309.81	22,782.23	48,990.27
4	EXPENSES :						
a.	Cost of Materials Consumed	292.15	24.37	327.76	316.52	520.32	559.34
b.	Purchases of Stock-in-Trade	13,606.02	8,658.90	12,551.80	22,264.92	21,236.46	44,641.67
c.	Change in inventory stock in trade	-79.72	-40.33	(223.85)	(120.04)	(234.68)	(89.09)
d.	Employee Benefits Expense	53.72	52.39	53.80	106.11	104.68	223.46
e.	Finance Costs	105.61	107.52	95.03	213.14	148.61	390.70
f.	Depreciation and Amortisation Expense	147.90	145.37	171.83	293.27	302.74	652.47
g.	Other Expenses	496.20	424.02	219.06	920.22	424.79	2,966.96
	Total Expenses	14,621.89	9,372.25	13,195.44	23,994.14	22,502.93	49,345.51
5	Profit Before Exceptional Items and Tax (3-4)	(455.95)	12,771.62	191.58	12,315.67	279.30	(355.24)
6	Exceptional Items						
7	Profit/ (Loss) Before Tax (5-6)	(455.95)	12,771.62	191.58	12,315.67	279.30	(355.24)
8	Tax Expense/(Benefits):						
i.	Current Tax	-7.39	7.39	(294.84)	-		378.11
ii.	Deferred Tax	-99.15	-		(99.15)		(507.69)
iii.	Previous Year Income Tax					79.88	
	Total Tax Expense (i+ii+iii)	(106.54)	7.39	(294.84)	(99.15)	79.88	(129.58)
9	Net Profit/(Loss) from continuing operations (7-8)	(349.41)	12,764.23	486.42	12,414.82	199.42	(225.66)
10	Profit/(loss) from discontinued operations						
11	Tax expenses of discontinued operations						
12	Profit/(loss) from Discontinued operations (after tax) (10-11)						
13	Profit/(loss) for the period (9+12)	(349.41)	12,764.23	486.42	12,414.82	199.42	(225.66)
	Other Comprehensive Income :						
A.)	(i) Items that will not be reclassified to Profit and Loss	-21.68	11.64	576.12	-10.04	576.12	500.38
	(ii) income tax relating to items that will not be reclassified to profit or loss	5.46	-2.93	(145.00)		(145.00)	(125.93)
					2.53		
B)	(i) items that will be reclassified to profit and loss account	0.73	1.09	(1.07)	1.82	(1.07)	3.89
	(ii) income tax relating to items that will be reclassified to profit or loss	-0.18	-0.27	0.27		0.27	(0.98)
					-0.46		
14	Total Other Comprehensive Income	(15.67)	9.53	430.32	(6.15)	430.32	377.35
15	Total comprehensive income (Comprising Profit (Loss) and Other Comprehensive Income for the period) (13+14)	(365.09)	12,773.75	916.75	12,408.67	629.75	151.69
16	Paid up Equity Share Capital (Face Value Rs.1 each)	18,598.36	18,598.36	18,598.36	18,598.36	18,598.36	18,598.36
17	Earning per Equity Share:						
	Equity shares of par value Rs 1 each						
	(EPS for three months ended periods are not annualised)						
	Basic	(0.02)	0.69	0.03	0.67	0.01	(0.01)
	Diluted	(0.02)	0.69	0.03	0.67	0.01	(0.01)
	**Including restated figures for the quarter ending June 25						

For Vikas Lifecare Limited

Sundeep Kumar Dhawan
Managing director
DIN : 09508137

Place: New Delhi
Date: 21-04-2026

VIKAS LIFECARE LIMITED
CIN: L25111DL1995PLC073719

STANDALONE BALANCE SHEET AS AT 30TH SEPTEMBER, 2025

Particulars	As at 30th September, 2025	As at 31st March, 2025
ASSETS		
Non-current Assets		
Property, Plant and Equipment	3,325.56	3,536.49
Investment Property	112.65	715.13
Capital Work in Process	103.84	65.31
Intangible Assets	639.67	686.69
ROU Assets	37.57	47.37
Financial Assets		
- Investments	47,248.97	4,840.65
- Trade Receivables	549.27	300.03
- Loans	1,151.48	390.65
- Other Financial Assets	250.62	28,338.16
Deferred Tax Assets (Net)	446.11	344.89
Other non current Assets	3,592.26	4,901.60
Total Non Current Assets	57,457.98	44,166.97
Current Assets		
Inventories	949.59	478.13
Financial Assets		
- Trade Receivables	10,550.46	12,322.67
- Cash & cash equivalents	613.64	524.02
- Loans	-	-
- Other Financial Assets	5,285.50	2,768.04
Other Current Assets	5,338.26	8,704.13
Assets Held for Sale	328.20	328.20
Total Current Assets	23,065.65	25,125.19
Total Assets	80,523.63	69,292.16
EQUITY AND LIABILITIES		
Equity		
Equity Share capital	18,598.36	18,598.36
Other Equity	48,304.60	35,898.29
Total Equity	66,902.96	54,496.64
Liabilities		
Non-current liabilities		
Financial Liabilities		
- Borrowings	2,776.51	3,851.71
-Lease Liabilities Non Current	20.45	30.46
- Other financial Liabilities	-	20.02
Provisions	21.24	18.05
Deferred Tax Liabilities (Net)	-	-
Other Non Current liabilities	390.00	390.00
Total Non Current Liabilities	3,208.20	4,310.24
Current Liabilities		
Financial Liabilities		
- Borrowings	4,293.68	496.78
-Lease Liabilities Current	19.50	18.13
- Trade Payables		
- Outstanding dues of micro enterprises & small enterprises	70.08	65.74
- Outstanding dues of creditors other than above	2,419.25	5,658.68
- Other Financial Liabilities	2,938.76	1,016.98
Provisions	2.16	1.67
Other Current Liabilities	342.49	2,536.05
Current Tax Liabilities (Net)	326.56	691.25
Total Current Liabilities	10,412.49	10,485.27
Total Liabilities	13,620.69	14,795.52
Total Equity & Liabilities	80,523.63	69,292.16

VIKAS LIFECARE LIMITED
CIN: L25111DL1995PLC073719
STANDALONE STATEMENT OF CASH FLOWS FOR THE PERIOD ENDED 30TH SEPTEMBER, 2025

Particulars	As at 30th September, 2025		For the Year Ended 31st March, 2025	
A. Cash flow from operating activities :				
Net Profit/(Loss) before tax for the year		12,315.67		(355.24)
<i>Adjustments for :</i>				
Depreciation & Amortization	293.27		652.47	
(Profit)\Loss on sale of PPE & Investment Property(net)	-1.00		-3.11	
Finance costs	211.19		387.95	
Payment of Lease Rent and Securities Deposit	-10.59		-18.37	
Profit on sale of Investment in Shares (net of charges, tax etc)	-20.56		-1,016.30	
Remeasurement of Financial Instruments (security deposits)	-7.51		405.26	
(Gain)\Loss on Fair Valuation of Investments	-		405.26	
Remeasurement of defined benefits through OCI	1.36		2.91	
Rental Income	-15.42		-53.05	
Prior Period adjustments	-2.35		-64.82	
Forfeiture Account			-510.00	
Interest Expenses on Lease Liabilities	1.95		2.75	
Dividend Income	-		-4.13	
Interest Income	-63.05	387.28	-376.23	-189.39
<i>Operating profit / (loss) before working capital changes</i>		12,702.95		(544.63)
<i>Adjustments for Working Capital Change:</i>				
Decrease/(Increase) in Inventories	-471.46		424.76	
Decrease/(Increase) in Trade receivables	1,522.98		1,244.72	
Decrease/(Increase) in Financial Assets & other assets	30,245.29		-31,334.08	
(Decrease)/Increase in Trade payables	-3,235.09		4,472.45	
(Decrease)/Increase in Other financial liabilities	1,901.76		6.01	
(Decrease)/Increase in Other liabilities	-2,189.88	27,773.60	2,415.03	(22,771.12)
Cash generated from operations		40,476.55		(23,315.75)
Tax Paid		-366.75		30.75
Net cash flow from operating activities (A)		40,109.79		(23,285.00)
B. Cash flow from investing activities				
Expenditure on acquisition of property, Plant and Equipment	-63.48		-1,270.00	
Acquisition of ROU Assets			-	
Proceeds from Sale of Property, Plant and Equipment	602.90		16.82	
Increase/Decrease in Loans	-760.83		527.36	
Acquisition of Investment in shares/MOU(Net)	-42,387.76		14,389.83	
Dividend Income	-		4.13	
Profit on sale of investments in shares through OCI	-		24.75	
Rent from Investment Property	15.42		53.05	
Forfeiture Account	-		510.00	
Interest received	63.05		376.23	
Net cash flow from / (used in) investing activities (B)		(42,530.69)		14,632.16
C. Cash flow from financing activities				
Proceeds/Repayment of short-term borrowings	3,796.90		-45.92	
Proceeds/Repayment of Equity share Capital	-		-	
Proceeds/Repayment of Non Current Borrowings	-1,075.20		2,080.51	
(Conversion)/Proceeds from Share Warrants	-		-	
Net Proceeds from right issue including Securities Premium	-		6,200.00	
Finance cost	-211.19		-387.95	
Net cash flow from / (used in) financing activities (C)		2,510.52		7,846.64
Net increase / (decrease) in Cash and cash equivalents (A+B+C)		89.62		(806.20)
Cash and cash equivalents at the beginning of the year		524.02		1,330.22
Cash and cash equivalents at the end of the year		613.64		524.02
Components of Cash & Cash Equivalents (Refer Note No. 13)				
Cash in hand		6.89		3.09
Cheques in Hand		-		-
Balances with Banks		606.75		520.93
Total Cash and Cash Equivalents		613.64		524.02

Information on Segment Reporting pursuant to Ind AS 108 - Operating Segments**Operating segments:**

Trading & Manufacturing Division -Agro
 Trading & Manufacturing Division -Polymers
 Trading Division -Infrastructure

Identification of segments:

The chief operational decision maker monitors the operating results of its business segments separately for the purpose of making decisions about resource allocation and performance assessment. Segment performance is evaluated based on profit and loss of the segment and is measured consistently with profit or loss in these financial Results. Operating segments have been identified on the basis of the nature of products and Services.

Segment revenue and results

The expenses and income which are not directly attributable to any business segment are shown as unallocable expenditure (net of unallocable income).

The measurement principles of segments are consistent with those used in preparation of these financial Results. There are no inter-segment transfers.

1. Revenue by Geographical Location

(Figures in Lakhs)

Particulars	Three months Ended			Half Year Ended		Year Ended
	For the period ended September 30th, 2025	For the period ended June 30th, 2025	For the period ended September 30th, 2024	For the period ended September 30th, 2025	For the period ended September 30th, 2024	For the period ended March 31st, 2025
Domestic	14,097.78	8869.19	13035.44	22,966.97	22,191.62	45,972.33
Export:-				-	-	385.28
Ghana						385.28
Total	14,097.78	8,869.19	13,035.44	22,966.97	22,191.62	46,357.62

2. Revenue by nature of products

Particulars	For the period ended September 30th, 2025	For the period ended June 30th, 2025	For the period ended September 30th, 2024	For the period ended September 30th, 2025	For the period ended September 30th, 2024	For the period ended March 31st, 2025
(a) Trading & Manufacturing Division -Polymers	441.80	306.28	514.12	748.08	862.09	1,753.87
(b) Trading & Manufacturing Division -Agro	12,607.36	7546.54	11236.03	20,153.90	18,092.48	37,908.90
(c) Trading & Manufacturing Division -Infrastructure	1,048.62	1016.37	1285.29	2,064.99	3,237.04	6,694.85
Total	14,097.78	8,869.19	13,035.44	22,966.97	22,191.61	46,357.62

3. Segment Results before tax and interest

Particulars	For the period ended September 30th, 2025	For the period ended June 30th, 2025	For the period ended September 30th, 2024	For the period ended September 30th, 2025	For the period ended September 30th, 2024	For the period ended March 31st, 2025
(a) Trading & Manufacturing Division -Polymers	20.50	27.13	108.96	47.62	166.07	32.61
(b) Trading & Manufacturing Division -Agro	228.70	170.33	245.33	399.04	446.40	1,091.50
(c) Trading & Manufacturing Division -Infrastructure	30.12	28.79	25.62	58.91	57.23	121.58
Sub Total	279.33	226.25	379.91	505.57	669.70	1,245.70
Less: Finance Cost	105.61	107.52	95.03	213.14	148.61	390.70
Add: Other Income	68.17	13,274.67	351.4	13,342.84	590.43	2,632.65
Less: Unallocated Expenses	697.82	621.78	444.7	1,319.60	832.21	3,842.90
Profit before tax	(455.95)	12,771.62	191.58	12,315.67	279.30	(355.24)
Less: Tax expenses	-106.54	7.39	-214.96	-99.15	79.88	(129.58)
Net profit/(loss) for the Period	(349.41)	12,764.23	406.54	12,414.82	199.42	(225.66)

4. Major Customers

(a)	For the Quarter ended September 2025 Revenue from one customer of the Segment Trading & Manufacturing Division - Agro represented approximately Rs. 1,727.73 Lacs of the total revenue.
(b)	For the Quarter ended June 2025 Revenue from two customers of the Segment Trading & Manufacturing Division - Agro represented approximately Rs. 1,007.48 Lacs, and Rs. 969.73 Lacs of the total revenue.
(c)	For the Quarter ended September 2024 Revenue from two customers of the Segment Trading & Manufacturing Division - Agro represented approximately Rs. 2,572.66 Lacs, and 1,386.33 Lacs of the total revenue.
(d)	For the Half Year ending September 2025, the company does not have major customers as per IND-AS 108.
(e)	For the Half Year ended September 2024 Revenue from three customers of the Segment Trading & Manufacturing Division - Agro represented approximately Rs. 2,650.15 Lacs, Rs. 2,573.62 Lacs and Rs. 2,572.66 Lacs of the total revenue.
(f)	For the Year ended March 2025 Revenue from one customer of the Segment Trading & Manufacturing Division - Agro represented approximately Rs. 4,980.92 Lacs of the total revenue.
(g)	Segment revenue and results include the respective amounts identifiable to each of the segments and amounts allocated on a reasonable basis.

For Vikas Lifecare Limited

Sundeep Kumar Dhawan
 Managing Director
 DIN:09508137

VIKAS LIFECARE LIMITED

CIN - L25111DL1995PLC073719

REGD OFF: VIKAS HOUSE,3,ARIHANT NAGAR ROHTAK ROAD,PUNJABI BAGH WEST,DELHI-110026 PH NO: 011-40450110 EMAIL - info@vikaslifecarelimited.com

Notes to unaudited standalone financial results for the Half Year ended September 30, 2025

1 Summary of Profit before impact of Fair Value Changes through Profit and Loss Account related to Investments

Particulars	Half Year Ended 30.09.2025	Year Ended 31.03.2025
	Unaudited	Audited
Profit Before Tax	12,315.67	(355.24)
Less: Reameasurement gain/(loss) on account investments fair valued through FVTPL	(377.24)	(1,959.75)
Profit of the company excluding impact of Reameasurement gain/(loss) on account investments fair valued through	12,692.91	1,604.51

2 The standalone financial results of the company have been prepared in accordance with Ind AS prescribed under Section 133 of the Companies Act 2013 (the Act) read with the relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015.

3 The above unaudited Standalone financial results have been reviewed and recommended by the Audit Committee and approved by the Board of Directors at their meeting at the Registered office held on 21st April, 2026. The auditors have issued an unmodified review report on the financial results for the quarter and Half year ended 30th September, 2025.

4 In accordance with Ind AS, the company has recognised actuarial gains or losses on actuarial valuation of the Defined Benefit Obligation in "Other Comprehensive Income".

5 The results of the Company are also available for investors at www.vikaslifecarelimited.com, www.bseindia.com and www.nseindia.com

6 Investment in Unquoted shares/securities is subject to fair valuation and such investments has been kept at book value.

7 The previous year figures have been regrouped / reclassified, wherever necessary to confirm to the current year presentation.

8 Investor Complaints

Pending at the beginning of the quarter	-
Received during the quarter	-
Disposed off during the quarter	-
Remaining unresolved at the end of the quarter	-

9 During the previous year, Eraaya Lifespaces Limited (ELL/holding company) acquired the Ebix Inc and all its global subsidiaries through successful bids approved by the debtors and plan sponsor as part of the Chapter 11 proceedings under the supervision of Dallas Court at the United States (U.S.).

As part of a consortium led by ELL, Vikas Lifecare Limited (VLL) contributed ₹ 2,977.27 million (equivalent US\$ 34.83 million) towards the acquisition of Ebix Inc. Further, an addendum agreement dated August 16, 2024, provided that in case of non-repayment by ELL, VLL may receive 51% shares of Ebix International Holdings Limited (EIHL) (the step down subsidiary of the Company). Owing to non-repayment by January 31, 2025, VLL invoked the Arbitration Clause of the Agreement.

During the quarter ended June 30, 2025, the arbitration proceedings were concluded through a settlement deed, and accordingly, 51% of equity shares of EIHL have been transferred to VLL and necessary adjustments have been made in the unaudited financial results (restated) for the quarter ended June 30, 2025. Further, the relevant applications, seeking requisite orders and/or approvals including regulatory approvals, wherever applicable, are to be obtained by the company. Further, ELL and Ebix Inc have been accorded specified rights in relation to the management and operations of EIHL and its subsidiaries, including participation in key decision-making and the ability to influence relevant financial and operational policies of EIHL and its subsidiaries. Based on management's assessment and in accordance with the principles laid down in Ind AS 110 Consolidated Financial Statements, the Company (VLL) does not presently exercise control over Ebix UK and its subsidiaries. Accordingly, the investment has been accounted for as an associate using the equity method in accordance with Ind AS 28 Investments in Associates and Joint Ventures.

The management of the Company is undertaking a comprehensive review of applicable compliance requirements and is actively coordinating with legal and regulatory advisors to ensure compliances, if any, in an expedite manner, considering the cross-border nature of the transactions.

10 Related Party Transactions

During the half year ended September 30, 2025, the Company entered into certain related party transactions. As per the provisions of Regulation 23 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, prior approval of the Shareholder of the listed entity is required for material related party transactions. As at the date of approval of these Financial Results, shareholders' approval of the Company for such material related party transactions yet been obtained.

Further, the company is in the process of evaluating the regulatory compliance requirements and obtaining the necessary approvals, where applicable. Management is also reviewing the supporting documentation and underlying business rationale in respect of the aforesaid transactions and will take appropriate actions, including providing additional disclosures, if considered necessary.

11 Transaction relating to Investment in IGL Genesis Technologies Limited

M/s Genesis Gas Solutions Private Limited ("GGPL") has entered into a Share Purchase Agreement with Vikas Lifecare Limited ("VLL") for the transfer of its investment in IGL Genesis Technologies Limited ("IGTL"). Pursuant to the said agreement, the shares were transferred in dematerialized form in May 2025.

However, as at the reporting date and the date of approval of these financial results, certain conditions precedent to the completion of the transaction, as stipulated in the Share Purchase Agreement, remain pending.

Further, the said transfer is subject to requisite approvals from the Board of Indraprastha Gas Limited ("IGL") and the Board of IGTL, in accordance with the terms of the Shareholders' cum Joint Venture Agreement ("SHA") entered into between GGPL and IGL, which requires consent of the joint venture partner for such transfer. Pending receipt of these approvals, the name of the shareholder as appearing in the register of members of IGTL continues to remain unchanged.

In view of the above, the transfer of shares has not been given effect in the books of account. The accounting treatment of the said investment will be determined upon completion of the transaction and receipt of the necessary approvals.

The necessary steps are being undertaken to obtain the required approvals and that stakeholders will be duly informed upon receipt of the same.

12 Tax Implications of Settlement Transaction

Pursuant to the transaction involving contribution of US\$ 34.83 million made by company towards acquisition of Ebix Inc. and subsequent settlement of same in accordance with the Settlement Agreement dated 14 May 2025, the Company has received 51% equity shares of Ebix UK.

The Company is currently evaluating the tax implications arising from the aforesaid transaction, including, inter alia, the appropriate characterization of the transaction, its taxability under applicable provisions of the Income tax Act, 1961.

Pending receipt of expert opinions from relevant tax and legal professionals, the Company has not recognized any tax impact, if applicable, in the accompanying financial results. Any tax liability or consequential financial impact arising from the outcome of such evaluation shall be appropriately accounted for in the financial statements for the financial year 2025-26, in accordance with the applicable accounting standards and prevailing tax laws.

13 Restated notes to unaudited standalone financial results for the quarter ended June 30, 2025

Note 1 of standalone unaudited financial results for the quarter ended June 30, 2025 should be read as below:

i Original Note no. 1 of unaudited standalone financial results for the quarter ended June 30, 2025

Particulars	Quarter Ended 30.06.2025	Year Ended 31.03.2025
	Unaudited	Audited
Profit before tax	-277.36	(355.24)
Less: Reameasurement gain/(loss)	-236.46	(1,959.75)
Profit of the company Excluding remeasurement	-40.89	1,604.51

ii Restated Note 1 of standalone unaudited financial results for the quarter ended June 30, 2025

Other Income includes profit or loss on remeasurement investment at fair value through profit and Loss Account, Summary of the same is depicted below:-

Particulars	Quarter Ended 30.06.2025	Year Ended 31.03.2025
	Unaudited	Audited
Profit before tax	12,771.62	(355.24)
Less: Reameasurement gain/(loss)	-236.46	(1,959.75)
Profit of the company Excluding remeasurement	13,008.08	1,604.51

iii Reason for restatement

Subsequent to the issuance of the previously reported financial results, additional information came to light indicating about transfer of shares of Ebix International Holding Limited (Ebix UK), a step down subsidiary of the Eraaya Lifespaces Limited to Vikas Lifecare Limited in pursuance of settlement deed, it was discovered that the same has not been accounted and disclosed in the financial results for the quarter ended June 30, 2025.

In accordance with the requirements of Ind AS 8 - Accounting Policies, Change in Accounting Estimates and Errors, such omission has been evaluated and the financial results have been restated to incorporate the necessary adjustments and disclosures and ensure appropriate effect and presentation in respect to such settlement.

iii Impact of restatement

Impact on Profit and Loss Account				
Particulars	April to June 30, 2025 (Reported)	April to June 30, 2025 (Restated)	Change	Nature
Cost				
Other Expenses	442.77	424.02	-18.75	Change in Exchange Rate Fluctuation Gain/Loss
Provision for Income Tax	2.67	7.39	4.72	Income Tax Provision on gain/loss arises on settlement of transaction
Income				
Other Income	244.45	13,274.67	13,030.22	Recognition of gain arises on settlement vide transfer of investment of Ebix International Holding and Change in Exchange Rate Fluctuation Gain/Loss
Profit/ (Loss) for the period (After Tax)	-280.03	12,764.23	13,044.25	Resultant Change due to above changes in cost and income
EPS				
Basic	-0.01	0.69	0.70	Resultant Change due to above changes in cost and income
Diluted	-0.01	0.69	0.70	

Impact on Balance Sheet			
Investment	Amount in Lakhs	Impact	Remarks
Investment in UK	42,841.35	Increase	Impact due to recognition of Investment related to transfer of shares of Ebix International Holdings in pursuance of settlement deed
Other Financial Assets	28,081.50	Decrease	
Other Current Liab.	1,710.88	Increase	
Current Tax Liabilities (Net)	4.72	Increase	

For Vikas Lifecare Limited

Sundeep Kumar Dhawan
Managing director
DIN : 09508137

Place: New Delhi
Date: 21-04-2026



Independent Auditor's Limited Review Report on the Quarterly and half yearly Unaudited Consolidated Financial Results of Vikas Lifecare Limited pursuant to the Regulations 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulation 2015, as amended Review Report

To the Board of Directors

Vikas Lifecare Limited

1. We have reviewed the accompanying statement of unaudited consolidated financial results of Vikas Lifecare Limited (the "Parent") and its subsidiaries (the parent and its subsidiaries together referred to as "the group") for the quarter and half year ended 30th September 2025 being submitted by the Parent pursuant to requirements of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations).
2. This statement is the responsibility of the Parent's Management and has been approved by the Parent's Board of Directors, our responsibility is to express a conclusion on the statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
4. The statement includes results of the following entities:
 - a. Shashi Beriwal And Company Private Limited
 - b. Genesis Gas Solutions Private Limited
 - c. Vikash Lifecare Investment Management LLC (wholly Owned subsidiary)
 - d. Vikas Sports Venture Private Limited(wholly Owned subsidiary)
 - e. IGL Genesis Technologies Limited (step down Associate)
 - f. Ebix International Holdings Limited (EIH) (Associate)

The Group holds 51% equity interest in Ebix International Holdings Limited; however, based on the contractual arrangements and governance structure, the Group exercises significant influence and does not have control over the said entity. Accordingly, the investment has been classified as an Associate and accounted for using the equity method in accordance with Ind AS 28. The said Associate has its own subsidiaries/associates, which are consolidated at the level of the Associate. The Group's share of profit/loss and net assets of the Associate includes the



impact of such subsidiaries/associates. These subsidiaries/associates have not been separately consolidated in the Group's consolidated financial results.

5. Based on our review conducted as stated in paragraph 3 and based on consideration of Management's certified financial results referred to in Paragraph 11 below, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable principles laid down in the accounting standard 34 Interim Financial Reporting (IND AS 34) prescribed under Section 133 of the Companies Act' 2013 read with relevant rules issued there under and other accounting principles generally accepted in India has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

Emphasis of Matters

6. We draw attention to Note 9 to the accompanying financial results which describes that during the previous year, Eraaya Lifespaces Limited ("ELL") had acquired the Ebix Inc and its global subsidiaries pursuant to Chapter 11 proceedings under the supervision of the Dallas Court, U.S. As further detailed in the said note, Vikas Lifecare Limited ("VLL"), as part of the consortium led by ELL, had contributed INR 2,977.27 million (equivalent to US\$ 34.83 million) towards the acquisition of Ebix Inc. In terms of an addendum agreement dated August 16, 2024, VLL was entitled to receive 51% equity shares of Ebix International Holdings Limited ("EIHL"), a subsidiary of the Ebix Inc, in the event of non-repayment by ELL. Upon such non-repayment by January 31, 2025, VLL invoked the arbitration clause, and the matter was settled during the quarter ended June 30, 2025 through a settlement deed. Pursuant thereto, 51% equity shares of EIHL have been transferred to VLL. Further, the requisite approvals, including regulatory approvals, as may be applicable for the aforesaid transaction, are in the process of being obtained by the Company. The management has represented that it is undertaking a comprehensive review of compliance requirements across jurisdictions and is actively coordinating with legal and regulatory advisors to regularize such compliances, considering the cross-border nature of the transaction
7. **Restatement of unaudited standalone financial results for the quarter ended June 30, 2025**
We draw attention to Note 13 to the accompanying financial results, which describes that unaudited standalone financial result for the quarter ended June 30, have been restated to reflect additional facts that came to management's attention subsequent to the issuance of the previously reported financial results. These developments relate to the transfer of shares of Ebix International Holding Limited (Ebix UK), a step down subsidiary of the Eraaya Lifespaces Limited in pursuance of settlement deed. Accordingly, the previously reported figures and disclosure in financial results have been restated to appropriately incorporate the effect and presentation in respect to such settlement.
8. **Related Party Transactions**
We draw attention to Note 10 to the financial results which describes which describes that during the half year ended September 30, 2025, the Company entered into certain related party transactions. As stated in the said note, in terms of Regulation 23 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, prior approval of the shareholders is required for material related party transactions; however, as at the date of approval of these financial results, such approval has not yet been obtained.



Further, the company is in the process of evaluating the regulatory compliance requirements and obtaining the necessary approvals, where applicable. Management is also reviewing the supporting documentation and underlying business rationale in respect of the aforesaid transactions and will take appropriate actions, including providing additional disclosures, if considered necessary.

9. Transaction relating to Investment in IGL Genesis Technologies Limited

We draw attention to Note 11 to the accompanying financial results, which describes that M/s Genesis Gas Solutions Private Limited ("GGPL") has entered into a Share Purchase Agreement with Vikas Lifecare Limited ("VLL") for the transfer of its investment in IGL Genesis Technologies Limited ("IGTL"), pursuant to which the shares were transferred in dematerialized form in May 2025. However, as at the reporting date and the date of approval of these financial results, certain conditions precedent to the completion of the transaction remains pending.

As further explained in the said note, the transfer is subject to requisite approvals from the Board of Indraprastha Gas Limited and the Board of IGTL, in accordance with the terms of the Shareholders' cum Joint Venture Agreement, and pending such approvals, the name of the shareholder as appearing in the register of members of IGTL continues to remain unchanged.

In view of the above, the transfer of shares has not been given effect in the books of account. The accounting treatment of the said investment will be determined upon completion of the transaction and receipt of the necessary approvals.

10. Tax Implications of Settlement Transaction

We draw attention to note 12 to the accompanying results, which describes that pursuant to the transaction involving contribution made by the Company towards acquisition of Ebix Inc. and subsequent settlement thereof, the Company has received 51% equity shares of Ebix UK in accordance with the Settlement Agreement dated 14 May 2025.

The Company is in the process of evaluating the tax implications arising from the aforesaid transaction, including the characterization of the transaction, its taxability under applicable laws, Pending completion of such evaluation and receipt of expert opinions, no tax impact, if any, has been recognized in the accompanying financial results.

Our conclusion is not modified in respect of above matters.

11. Other Matters

- i. One associate, namely Ebix International Holdings Limited (EIH), whose interim unaudited consolidated financial results reflect Group's share of loss after tax of Rs. 11263.76 Lakhs and Rs. 11412.46 Lakhs, other comprehensive income of Rs. 54.672 Lakhs and Rs. 62.77 Lakhs for the quarter ended September 2025 and for the half year ended September 30, 2025 as considered in the consolidated unaudited financial results is based on the basis of management certified financial information which has been provided to us.

Though the financial information of the said associate has not been reviewed by us, it has been subjected to review by the other auditor as part of the review of the consolidated financial information of Ebix Inc. (which is holding company of EIH) whose report has been furnished to us by the Management. Accordingly, our conclusion on the consolidated unaudited financial results, in so far as it relates to



KSMC & ASSOCIATES

Chartered Accountants

the amounts and disclosures included in respect of the said associate, is solely based on the report of such other auditor and the procedures performed by us as stated in paragraph 3 above.

- ii. We have not reviewed the financial information of 3 subsidiaries and 1 step down associate included in the consolidated financial results, whose financial information reflects total revenue of Rs. 34.88 lakhs and Rs. 404.05 lakhs (before consolidation adjustments), loss after tax of Rs. 295.12 lakhs and Rs. 410.38 lakhs (before consolidation adjustments), other comprehensive income of Rs. (0.70 Lakhs) and Rs. (0.70 Lakhs) for the quarter and half year ended on 30 Sep 2025 respectively, total assets of Rs. 5622.24 Lakhs and net cash inflow of Rs 26.93 lakhs for the half year ending 30th Sep 2025. The financial information of these entities has been certified by the respective managements and furnished to us, and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these entities, is based solely on such financial information.

Further, the aforesaid figures include the share of loss of Rs. 133.76 lakhs and Rs. 258.21 lakhs pertaining to an associate of one of these subsidiaries for the quarter and half year ended on 30 Sep 2025. The financial results of this associate have been reviewed by another auditor, whose report has been furnished to us by the management. Our conclusion, insofar as it relates to the amounts and disclosures pertaining to the said associate, is based solely on the report of such other auditor.

Our conclusion is not modified in respect of above matters.

For KSMC & Associates
Chartered Accountants
FRN: 035565N



CA SACHIN SINGHAL
(Partner)

M. No.: 505732

UDIN: 26505732HLOS893211

Place: New Delhi

Date: 21.04.2026

VIKAS LIFECARE LIMITED

REGD OFF: VIKAS HOUSE,3,ARIHANT NAGAR ROHTAK ROAD,PUNJABI BAGH WEST,DELHI-110026 PH NO: 011-40450110 EMAIL - info@vikaslifecarelimited.com

UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED 30TH SEPTEMBER, 2025

Sr. No.	Particulars	Three Months Ended			Half Year Ended		Year Ended
		30-Sep-25	30-Jun-25	30-Sep-24	30-Sep-25	30-Sep-24	31-Mar-25
		Unaudited	Unaudited-Restated	Unaudited	Unaudited**	Unaudited	Audited
1	Revenue from Operations						
a.	Revenue from Operations	14,132.66	9,238.36	13,487.63	23,371.02	22,696.87	48,002.24
2	Other Income	86.45	13,326.72	334.92	13,413.17	559.90	2,596.27
3	Total Income (1+2)	14,219.10	22,565.08	13,822.56	36,784.19	23,256.76	50,598.52
4	EXPENSES :						
a.	Cost of Materials Consumed	292.15	24.37	547.54	316.52	740.10	1,709.66
b.	Purchases of Stock-in-Trade	13,676.51	9,007.67	12,622.32	22,684.17	21,387.61	44,861.43
c.	Change in inventory of finished goods, work in progress and stock in trade	-105.16	-88.24	(175.86)	-193.40	(235.11)	(72.00)
d.	Employee Benefits Expense	111.11	106.99	110.98	218.10	209.56	441.67
e.	Finance Costs	183.57	115.50	103.25	299.07	168.92	457.11
f.	Depreciation and Amortisation Expense	150.19	147.78	184.58	297.97	315.49	673.54
g.	Other Expenses	521.07	464.94	346.25	986.01	583.44	3,222.16
	Total Expenses	14,829.44	9,779.01	13,739.07	24,608.45	23,170.01	51,293.57
5	Profit Before Exceptional Items and Tax (3-4)	(610.34)	12,786.08	83.48	12,175.74	86.75	(695.06)
6	Exceptional Items	-	-	-	-	-	-
	Share in profit (Loss) in Associate Company	-11,397.51	-273.15	(168.92)	(11,670.66)	(168.92)	(591.87)
7	Profit/ (Loss) Before Tax (5-6)	(12,007.85)	12,512.93	(85.44)	505.08	(82.17)	(1,286.93)
8	Tax Expense/(Benefits):						
	i. Current Tax	-12.66	12.66	(262.40)	-	79.88	378.11
	ii. Deferred Tax	-99.15	-	(38.41)	-99.15	(38.41)	(592.66)
	iii. Previous Year Income Tax	-	-	-	-	-	19.16
	Total Tax Expense (i+ii+iii)	(111.81)	12.66	(300.82)	(99.15)	41.47	(195.39)
9	Net Profit/(Loss) from continuing operations (7-8)	(11,896.04)	12,500.27	215.38	604.22	(123.64)	(1,091.54)
10	Profit/(loss) from discontinued operations						-
11	Tax expenses of discontinued operations						-
12	Profit/(loss) from Discontinued operations (after tax) (10-11)						
13	Profit/(loss) for the period (9+12)	(11,896.04)	12,500.27	215.38	604.22	(123.64)	(1,091.54)
	Other Comprehensive Income :						
	A.) (i) Items that will not be reclassified to Profit and Loss	-22.38	11.64	568.89	-10.74	576.12	506.03
	(ii) income tax relating to items that will not be reclassified to profit or loss	5.46	-2.93	(143.18)	2.53	(145.00)	(127.35)
	B) (i) items that will be reclassified to profit and loss account	0.73	1.09	0.21	1.82	(0.24)	-
	(ii) income tax relating to items that will be reclassified to profit or loss	-0.18	-0.27	(0.05)	-0.46	0.06	-
	Share of Other Comprehensive Income of associates	54.67	8.10	-	62.77	-	-
14	Total Other Comprehensive Income	38.30	17.63	425.86	55.92	430.95	378.68
15	Total comprehensive income (Comprising Profit (Loss) and Other Comprehensive Income for the period) (13+14)	(11,857.75)	12,517.89	641.24	660.15	307.31	(712.85)
16	Profit for the period attributable to:						
	Shareholders of the Company	-11,895.22	12,499.59	238.97	604.36	(90.58)	(1,061.39)
	Non-controlling interests	-0.83	0.69	(23.59)	(0.14)	(33.06)	(30.14)
		(11,896.05)	12,500.27	215.38	604.22	(123.64)	(1,091.54)
17	Other comprehensive income for the period attributable to:						
	Shareholders of the Company	38.30	17.63	425.84	55.92	430.92	378.04
	Non-controlling interests	-	-	0.03	-	0.03	0.06
		38.30	17.63	425.87	55.92	430.95	378.10
18	Total comprehensive income for the period attributable to:						
	Shareholders of the Company	-11,856.93	12,517.21	664.81	660.29	340.34	(683.36)
	Non-controlling interests	-0.83	0.69	(23.56)	(0.14)	(33.03)	(30.08)
		(11,857.75)	12,517.90	641.25	660.15	307.31	(713.44)
19	Paid up Equity Share Capital (Face Value Rs.1 each)	18,598.36	18,598.36	18,598.36	18,598.36	18,598.36	18,598.36
20	Earning per Equity Share:						
	Equity shares of par value Rs 1 each						
	Basic	-0.64	0.67	0.03	0.03	0.02	(0.04)
	Diluted	-0.64	0.67	0.03	0.03	0.02	(0.04)
	**Includes restated figures for the quarter ended 30th June 2025						

VIKAS LIFECARE LIMITED
CIN: L25111DL1995PLC073719
CONSOLIDATED BALANCE SHEET AS AT 30th SEPTEMBER, 2025

Particulars	As at September 30, 2025	As at March 31, 2025
ASSETS		
Non-current Assets		
Property, Plant and Equipment	3,393.55	3,586.42
Capital Work in Process	103.84	65.31
Investment Property	112.65	715.13
Intangible Assets	639.67	686.69
Right of Use assets	37.57	47.37
Goodwill	1,043.95	1,043.95
Financial Assets	-	
- Investments	37,617.81	5,396.33
- Trade Receivables	549.27	293.17
- Loans	1,151.48	390.65
- Other Financial Assets	254.03	28,341.57
Deferred Tax Assets (Net)	550.86	449.65
Income Tax assets (Net)	-	4.97
Other non current Assets	3,592.26	4,901.60
Total Non Current Assets	49,046.92	45,922.83
Current Assets		
Inventories	1,024.33	479.51
Financial Assets	-	
- Trade Receivables	10,989.53	12,801.38
- Cash & cash equivalents	690.60	573.06
- Loans	219.64	11.11
- Other Financial Assets	7,011.52	3,744.38
Other Current Assets	3,805.12	9,065.55
Current Tax Asset (Net)	12.58	
Assets Held for Sale	328.20	328.20
Total Current Assets	24,081.51	27,003.18
Total Assets	73,128.45	72,926.00
EQUITY AND LIABILITIES		
Equity		
Equity Share capital	18,598.36	18,598.36
Other Equity	36,653.63	34,577.92
Equity attributable to shareholders of the Company	55,251.99	53,176.28
Non-controlling interests	144.12	144.27
Total Equity	55,396.12	53,320.55
Liabilities		
Non-current liabilities		
Financial Liabilities	-	
- Borrowings	2,776.51	3,851.71
- Lease Liabilities	20.45	30.46
- Other financial Liabilities	-	20.02
Provisions	48.29	45.10
Deferred Tax Liabilities (Net)	-	-
Other Non Current liabilities	390.00	390.00
Total Non Current Liabilities	3,235.25	4,337.29
Current Liabilities		
Financial Liabilities	-	
- Borrowings	6,882.40	3,769.70
- Lease Liabilities	19.50	18.13
- Trade Payables	-	
- Outstanding dues of micro enterprises & small enterprises	70.20	104.33
- Outstanding dues of creditors other than above	2,607.69	5,871.18
- Other Financial Liabilities	2,967.34	1,051.43
Provisions	3.46	2.97
Other Current Liabilities	1,619.93	3,759.16
Current Tax Liabilities (Net)	326.56	691.25
Total Current Liabilities	14,497.10	15,268.15
Total Liabilities	17,732.34	19,605.44
Total Equity & Liabilities	73,128.45	72,926.00

VIKAS LIFECARE LIMITED
CIN: L25111DL1995PLC073719
CONSOLIDATED STATEMENT OF CASH FLOWS FOR THE PERIOD ENDED SAEPTEMBER 30, 2025

Particulars	For the Year Ended SEPTEMBER 30, 2025		For the Year Ended March 31, 2025	
A. Cash flow from operating activities :				
Net Profit/(Loss) before tax for the year		11,917.53		(1,310.45)
<i>Adjustments for :</i>				
Depreciation & Amortization	297.97		673.54	
(Profit)Loss on sale of PPE & Investment Property(net)	(1.00)		24.06	
Finance costs	294.44		437.54	
Payment of Lease Rent & Security Deposit	(10.59)		(18.37)	
Profit on sale of Investment in Shares (net of charges, tax etc)	(20.56)		(1,016.30)	
Remeasurement of Financial Instruments (security deposits)	(7.51)		405.26	
Foreign Exchange gain	(0.70)		(0.58)	
(Gain)Loss on Fair Valuation of Investments	-		2,365.01	
Assets Written Off	-		0.11	
Remeasurement of defined benefits through OCI	1.36		4.67	
Rental Income	(17.07)		(53.05)	
Prior Period adjustments	(2.35)		(83.98)	
Forfeiture Account	-		(510.00)	
Interesrt Expenses on Lease Liability	1.95		2.75	
Dividend Income	-		(4.13)	
Interest Income	(132.03)	403.89	(337.14)	1,889.38
<i>Operating profit / (loss) before working capital changes</i>		12,321.43		578.94
<i>Adjustments for Working Capital Change:</i>				
Decrease/(Increase) in Inventories	(544.81)		441.85	
Decrease/(Increase) in Trade receivables	1,434.49		1,663.25	
Decrease/(Increase) in Financial Assets & other assets	27,671.74		(32,430.01)	
(Decrease)/Increase in Trade payables	(3,300.40)		4,503.20	
(Decrease)/Increase in Other financial liabilities	1,890.36		40.26	
(Decrease)/Increase in Other liabilities	1,492.02		2,947.92	
(Decrease)/Increase in Provisions	-	28,643.39	3.56	(22,829.97)
Cash generated from operations		40,964.82		(22,251.04)
Tax Paid		(366.75)		30.75
Net cash flow from operating activities (A)		40,598.06		(22,220.32)
B. Cash flow from investing activities				
Expenditure on acquisition of property, Plant and Equipment	(86.22)		(1,270.00)	
Proceeds from Sale of Property, Plant and Equipment	602.90		74.72	
Increase/Decrease in Loans	(760.83)		(629.01)	
Acquisition of Investment in shares/MOU(Net)	(42,386.76)		11,524.51	
Proceeds from sale of Investments	258.20		-	
Dividend Income	-		4.13	
Profit on sale of investments in shares through OCI	-		24.75	
Forefeiture Account	-		510.00	
Rent from Investment Property	17.07		53.05	
Interest received	132.03		337.14	
Net cash flow from / (used in) investing activities (B)		(42,223.61)		10,629.29
C. Cash flow from financing activities				
Proceeds/Repayment of short-term borrowings	3,112.72		2,913.96	
Proceeds/Repayment of Equity share Capital	0.00		23.54	
Proceeds/Repayment from Term Loans	-		-	
Proceeds/Repayment of Non Current Borrowings	(1,075.20)		2,080.51	
Proceeds from Share Warrants	-		-	
Net Proceeds from right issue including Securities Premium	-		6,200.00	
Finance cost	(294.44)		(437.54)	
Net cash flow from / (used in) financing activities (C)	1,743.09	1,743.09		10,780.48
Net increase / (decrease) in Cash and cash equivalents (A+B+C)		117.55		(810.54)
Cash and cash equivalents at the beginning of the year		573.06		1,383.61
Cash and Cash Equivalent at the Investment of Subsidiary				
Cash and cash equivalents at the end of the year		690.61		573.06
Components of Cash & Cash Equivalents (Refer Note No. 13)				
Cash in hand		36.54		25.38
Cheques in Hand		-		-
Balances with Banks		654.07		547.68
Total Cash and Cash Equivalents		690.61		573.06

VIKAS LIFECARE LIMITED

CIN: L25111DL1995PLC073719

NOTES FORMING PART OF THE UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE HALF YEAR AND QUARTER ENDED 30th SEPTEMBER, 2025

Information on Segment Reporting pursuant to Ind AS 108 - Operating Segments

Operating segments:

Trading & Manufacturing Division -Agro
Trading & Manufacturing Division -Polymers
Trading Division -Infrastructure
Trading Division- Gas Meter

Identification of segments:

The chief operational decision maker monitors the operating results of its business segments separately for the purpose of making decisions about resource allocation and performance assessment. Segment performance is evaluated based on profit and loss of the segment and is measured consistently with profit or loss in these financial Results. Operating segments have been identified on the basis of the nature of products and Services.

Segment revenue and results

The expenses and income which are not directly attributable to any business segment are shown as unallocable expenditure (net of unallocable income).

The measurement principles of segments are consistent with those used in preparation of these financial Results. There are no inter-segment transfers.

1.

Particulars	Three months Ended			Half Year Ended		Year Ended
	For the period ended September 30th, 2025	For the period ended June 30th, 2025	For the period ended September 30th, 2024	For the period ended September 30th, 2025	For the period ended September 30th, 2024	For the period ended March 31st, 2025
Domestic	14,132.66	9238.36	13487.45	23,371.02	22696.68	47,616.95
Export:-	-	-	-	-	-	385.28
Ghana	-	-	-	-	-	385.28
Total	14,132.66	9,238.36	13,487.45	23,371.02	22,696.68	48,002.24

2. Revenue by nature of products

Particulars	For the period ended September 30th, 2025	For the period ended June 30th, 2025	For the period ended September 30th, 2024	For the period ended September 30th, 2025	For the period ended September 30th, 2024	For the period ended March 31st, 2025
(a) Trading & Manufacturing Division -Polymers	441.80	306.28	514.12	748.08	862.09	1,753.87
(b) Trading & Manufacturing Division -Agro	12,607.36	7546.54	11474.94	20,153.90	18,331.40	37,908.90
(c) Trading & Manufacturing Division -Infrastructure	1,130.54	1307.8	1285.29	2,438.34	3,237.04	8,034.58
(d) Trading Division- Gas Meter	-47.04	77.75	213.09	30.71	266.14	304.89
Total	14,132.66	9,238.36	13,487.44	23,371.02	22,696.68	48,002.24

3. Segment Results before tax and interest

Particulars	For the period ended September 30th, 2025	For the period ended June 30th, 2025	For the period ended September 30th, 2024	For the period ended September 30th, 2025	For the period ended September 30th, 2024	For the period ended March 31st, 2025
(a) Trading & Manufacturing Division -Polymers	20.50	27.13	108.96	47.62	166.07	32.61
(b) Trading & Manufacturing Division -Agro	228.70	170.33	264.17	399.04	465.24	1,091.50
(c) Trading & Manufacturing Division -Infrastructure	87.70	34.14	25.62	121.84	57.23	292.83
(d) Trading Division- Gas Meter	-67.75	62.96	-74.04	(4.79)	-53.20	86.22
Sub Total	269.16	294.56	324.71	563.72	635.34	1,503.16
Less: Finance Cost	183.57	115.50	103.26	299.07	168.92	457.11
Add: Other Income	86.45	13,326.72	335.75	13,413.17	559.90	2,596.27
Less: Unallocated Expenses	12,179.88	992.86	642.65	13,172.74	1,108.48	4,929.26
Profit before tax	-12,007.85	12,512.93	-85.46	505.08	-82.17	-1,286.93
Less: Tax expenses	-111.81	12.66	-253.37	-99.15	41.47	(195.39)
Net profit/(loss) for the Period	-11,896.04	12,500.27	167.91	604.22	-123.64	-1,091.54

4. Major Customers

(a)	For the Quarter ended September 2025 Revenue from one customer of the Segment Trading & Manufacturing Division - Agro represented approximately Rs. 1,727.73 Lacs of the total revenue.
(b)	For the Quarter ended June 2025 Revenue from two customers of the Segment Trading & Manufacturing Division - Agro represented approximately Rs. 1,007.48 Lacs, and Rs. 969.73 Lacs of the total revenue.
(c)	For the Quarter ended September 2024 Revenue from two customers of the Segment Trading & Manufacturing Division - Agro represented approximately Rs. 2,572.66 Lacs, and 1,386.33 Lacs of the total revenue.
(d)	For the Half Year ending September 2025, the company does not have major customers as per IND-AS 108.
(e)	For the Half Year ended September 2024 Revenue from three customers of the Segment Trading & Manufacturing Division - Agro represented approximately Rs. 2,650.15 Lacs, Rs. 2,573.62 Lacs and Rs. 2,572.66 Lacs of the total revenue.
(f)	For the Year ended March 2025 Revenue from one customer of the Segment Trading & Manufacturing Division - Agro represented approximately Rs. 4,980.92 Lacs of the total revenue.
(g)	Segment revenue and results include the respective amounts identifiable to each of the segments and amounts allocated on a reasonable basis.

For Vikas Lifecare Limited

Sundeep Kumar Dhawan
Managing Director
DIN:09508137

VIKAS LIFECARE LIMITED

CIN - L25111DL1995PLC073719

REGD OFF: VIKAS HOUSE,3,ARIHANT NAGAR ROHTAK ROAD,PUNJABI BAGH WEST,DELHI-110026 PH NO: 011-40450110 EMAIL - info@vikaslifecarelimited.com

Notes to unaudited consolidated financial results for the Half Year ended September 30, 2025

1 Summary of Profit before impact of Fair Value Changes through Profit and Loss Account related to Investments

Particulars	Half Year Ended 30.09.2025	Year Ended 31.03.2025
	Unaudited	Audited
Profit Before Tax	505.08	(1,286.93)
Less: Reameasurement gain/(loss) on account investments fair valued through FVTPL	(377.24)	(1,959.75)
Profit of the company excluding impact of Reameasurement gain/(loss) on account investments fair valued through	882.32	672.82

2 The consolidated financial results of the company have been prepared in accordance with Ind AS prescribed under Section 133 of the Companies Act 2013 (the Act) read with the relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015.

3 The above unaudited consolidated financial results have been reviewed and recommended by the Audit Committee and approved by the Board of Directors at their meeting at the Registered office held on 21 April, 2026. The auditors have issued an unmodified review report on the financial results for the quarter and Half year ended 30th September, 2025.

4 In accordance with Ind AS, the company has recognised actuarial gains or losses on actuarial valuation of the Defined Benefit Obligation in "Other Comprehensive Income".

5 The results of the Company are also available for investors at www.vikaslifecarelimited.com, www.bseindia.com and www.nseindia.com

6 Investment in Unquoted shares/securities is subject to fair valuation and such investments has been kept at book value.

7 The previous year figures have been regrouped / reclassified, wherever necessary to confirm to the current year presentation.

8 Investor Complaints

Pending at the beginning of the quarter	-
Received during the quarter	-
Disposed off during the quarter	-
Remaining unresolved at the end of the quarter	-

9 During the previous year, Eraaya Lifespaces Limited (ELL/holding company) acquired the Ebix Inc and all its global subsidiaries through successful bids approved by the debtors and plan sponsor as part of the Chapter 11 proceedings under the supervision of Dallas Court at the United States (U.S.).

As part of a consortium led by ELL, Vikas Lifecare Limited (VLL) contributed ₹ 2,977.27 million (equivalent US\$ 34.83 million) towards the acquisition of Ebix Inc. Further, an addendum agreement dated August 16, 2024, provided that in case of non-repayment by ELL, VLL may receive 51% shares of Ebix International Holdings Limited (EIHL) (the step down subsidiary of the Company). Owing to non-repayment by January 31, 2025, VLL invoked the Arbitration Clause of the Agreement.

During the quarter ended June 30, 2025, the arbitration proceedings were concluded through a settlement deed, and accordingly, 51% of equity shares of EIHL have been transferred to VLL and necessary adjustments have been made in the unaudited financial results (restated) for the quarter ended June 30, 2025.

Further, the relevant applications, seeking requisite orders and/or approvals including regulatory approvals, wherever applicable, are to be obtained by the company. Further, ELL and Ebix Inc have been accorded specified rights in relation to the management and operations of EIHL and its subsidiaries, including participation in key decision-making and the ability to influence relevant financial and operational policies of EIHL and its subsidiaries. Based on management's assessment and in accordance with the principles laid down in Ind AS 110 Consolidated Financial Statements, the Company (VLL) does not presently exercise control over Ebix UK and its subsidiaries. Accordingly, the investment has been accounted for as an associate using the equity method in accordance with Ind AS 28 Investments in Associates and Joint Ventures.

The management of the Company is undertaking a comprehensive review of applicable compliance requirements and is actively coordinating with legal and regulatory advisors to ensure compliances, if any, in an expedite manner, considering the cross-border nature of the transactions.

10 Related Party Transactions

During the half year ended September 30, 2025, the Company entered into certain related party transactions. As per the provisions of Regulation 23 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, prior approval of the Shareholder of the listed entity is required for material related party transactions. As at the date of approval of these Financial Results, shareholders' approval of the Company for such material related party transactions yet been obtained.

Further, the company is in the process of evaluating the regulatory compliance requirements and obtaining the necessary approvals, where applicable. Management is also reviewing the supporting documentation and underlying business rationale in respect of the aforesaid transactions and will take appropriate actions, including providing additional disclosures, if considered necessary.

11 Transaction relating to Investment in IGL Genesis Technologies Limited

M/s Genesis Gas Solutions Private Limited ("GGPL") has entered into a Share Purchase Agreement with Vikas Lifecare Limited ("VLL") for the transfer of its investment in IGL Genesis Technologies Limited ("IGTL"). Pursuant to the said agreement, the shares were transferred in dematerialized form in May 2025.

However, as at the reporting date and the date of approval of these financial results, certain conditions precedent to the completion of the transaction, as stipulated in the Share Purchase Agreement, remain pending.

Further, the said transfer is subject to requisite approvals from the Board of Indraprastha Gas Limited ("IGL") and the Board of IGTL, in accordance with the terms of the Shareholders' cum Joint Venture Agreement ("SHA") entered into between GGPL and IGL, which requires consent of the joint venture partner for such transfer. Pending receipt of these approvals, the name of the shareholder as appearing in the register of members of IGTL continues to remain unchanged.

In view of the above, the transfer of shares has not been given effect in the books of account. The accounting treatment of the said investment will be determined upon completion of the transaction and receipt of the necessary approvals.

The necessary steps are being undertaken to obtain the required approvals and that stakeholders will be duly informed upon receipt of the same.

12 Tax Implications of Settlement Transaction

Pursuant to the transaction involving contribution of US\$ 34.83 million made by company towards acquisition of Ebix Inc. and subsequent settlement of same in accordance with the Settlement Agreement dated 14 May 2025, the Company has received 51% equity shares of Ebix UK.

The Company is currently evaluating the tax implications arising from the aforesaid transaction, including, inter alia, the appropriate characterization of the transaction, its taxability under applicable provisions of the Income tax Act, 1961.

Pending receipt of expert opinions from relevant tax and legal professionals, the Company has not recognized any tax impact, if applicable, in the accompanying financial results. Any tax liability or consequential financial impact arising from the outcome of such evaluation shall be appropriately accounted for in the financial statements for the financial year 2025-26, in accordance with the applicable accounting standards and prevailing tax laws.

13 Restated notes to unaudited consolidated financial results for the quarter ended June 30, 2025

Note 1 of consolidated unaudited financial results for the quarter ended June 30, 2025 should be read as below:

i Original Note no. 1 of unaudited consolidated financial results for the quarter ended June 30, 2025

Particulars	Quarter Ended 30.06.2025	Year Ended 31.03.2025
	Unaudited	Audited
Profit before tax	-387.33	(1,286.93)
Less: Reameasurement gain/(loss)	-236.46	(1,959.75)
Profit of the company Excluding remeasurement	-150.87	672.82

i Restated Note 1 of consolidated unaudited financial results for the quarter ended June 30, 2025

Other Income includes profit or loss on remeasurement investment at fair value through profit and Loss Account, Summary of the same is depicted below:-

Particulars	Quarter Ended 30.06.2025	Year Ended 31.03.2025
	Unaudited	Audited
Profit before tax	12,512.93	(1,286.93)
Less: Reameasurement gain/(loss)	-236.46	(1,959.75)
Profit of the company Excluding remeasurement	12,749.39	672.82

ii Reason for restatement

Subsequent to the issuance of the previously reported financial results, additional information came to light indicating about transfer of shares of Ebix International Holding Limited (Ebix UK), a step down subsidiary of the Eraaya Lifespaces Limited to Vikas Lifecare Limited in pursuance of settlement deed, it was discovered that the same has not been accounted and disclosed in the financial results for the quarter ended June 30, 2025.

In accordance with the requirements of Ind AS 8 - Accounting Policies, Change in Accounting Estimates and Errors, such omission has been evaluated and the financial results have been restated to incorporate the necessary adjustments and disclosures and ensure appropriate effect and presentation in respect to such settlement.

iii Impact of restatement

Impact on Profit and Loss Account				
Particulars	April to June 30, 2025 (Reported)	April to June 30, 2025 (Restated)	Change	Nature
Cost				
Other Expenses	483.69	464.94	-18.75	Change in Exchange Rate Fluctuation Gain/Loss
Provision for Income Tax	7.95	12.66	4.72	Income Tax Provision on gain/loss arises on settlement of transaction
Income				
Other Income				Recognition of gain arises on settlement vide transfer of investment of Ebix International Holding and Change in Exchange Rate Fluctuation Gain/Loss
Share in profit (Loss) in Associate Company	-124.45	-273.15	-148.70	
Profit/ (Loss) for the period (After Tax)				Resultant Change due to above changes in cost and income
Other Comprehensive Income	-395.27	12,500.27	12,895.54	
Profit for the period attributable to:	9.53	17.63	8.10	
Shareholders of the Company	-395.97	12,499.59	12,895.56	Resultant Change due to above changes in cost and income
Other comprehensive income for the period attributable to:				
Shareholders of the Company	9.53	17.63	8.10	
EPS				
Basic	-0.02	0.67	0.69	
Diluted	-0.02	0.67	0.69	

Impact on Balance Sheet			
Investment	Amount in Lakhs	Impact	Remarks
Investment in UK	42,931.91	Increase	Impact due to recognition of Investment related to transfer of shares of Ebix International Holdings in pursuance of settlement deed
Other Equity-FCTR Reserve	231.16	Increase	
Other Financial Assets	28,081.50	Decrease	
Other Current Liab.	1,710.88	Increase	
Current Tax Liabilities (Net)	4.72	Increase	

For Vikas Lifecare Limited

Sundeep Kumar Dhawan
Managing director
DIN : 09508137

Place: New Delhi
Date: 21-04-2026



Independent Auditor's Limited Review Report on the Quarterly and Nine Months Unaudited Standalone Financial Results of Vikas Lifecare Limited pursuant to the Regulations 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulation 2015, as amended
Limited Review Report

To The Board of Directors

Vikas Lifecare Limited

1. We have reviewed the accompanying statement of unaudited standalone financial results of Vikas Lifecare Limited for the quarter and nine months ended 31st Dec, 2025 and being submitted by the company pursuant to requirements of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations).
2. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to express a conclusion on the statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable Ind AS 34 and other recognized accounting practices and policies generally accepted in India has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

Emphasis of Matters

5. We draw attention to Note 9 to the accompanying financial results which describes that during the previous year, Eraaya Lifespaces Limited ("ELL") had acquired the Ebix Inc and its global subsidiaries pursuant to Chapter 11 proceedings under the supervision of the Dallas Court, U.S. As further detailed in the said note, Vikas Lifecare Limited ("VLL"), as part of the consortium led by ELL, had contributed INR 2,977.27 million (equivalent to US\$ 34.83 million) towards the acquisition of Ebix Inc. In terms of an addendum agreement dated August 16, 2024, VLL was entitled to receive 51% equity shares of Ebix International Holdings Limited ("EIHL"), a subsidiary of the Ebix Inc, in the event of non-repayment by ELL. Upon such non-repayment by January 31, 2025,



VLL invoked the arbitration clause, and the matter was settled during the quarter ended June 30, 2025 through a settlement deed. Pursuant thereto, 51% equity shares of EIHL have been transferred to VLL. Further, the requisite approvals, including regulatory approvals, as may be applicable for the aforesaid transaction, are in the process of being obtained by the Company. The management has represented that it is undertaking a comprehensive review of compliance requirements across jurisdictions and is actively coordinating with legal and regulatory advisors to regularize such compliances, considering the cross-border nature of the transaction

6. Restatement of unaudited standalone financial results for the quarter ended June 30, 2025

We draw attention to Note 13 to the accompanying financial results, which describes that unaudited standalone financial result for the quarter ended June 30, have been restated to reflect additional facts that came to management's attention subsequent to the issuance of the previously reported financial results. These developments relate to the transfer of shares of Ebix International Holding Limited (Ebix UK), a step down subsidiary of the Eraaya Lifespaces Limited in pursuance of settlement deed. Accordingly, the previously reported figures and disclosure in financial results have been restated to appropriately incorporate the effect and presentation in respect to such settlement.

7. Related Party Transactions

We draw attention to Note 10 to the accompanying financial results which describes which describes that during the half year ended September 30, 2025, the Company entered into certain related party transactions. As stated in the said note, in terms of Regulation 23 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, prior approval of the shareholders is required for material related party transactions; however, as at the date of approval of these financial results, such approval has not yet been obtained.

Further, the company is in the process of evaluating the regulatory compliance requirements and obtaining the necessary approvals, where applicable. Management is also reviewing the supporting documentation and underlying business rationale in respect of the aforesaid transactions and will take appropriate actions, including providing additional disclosures, if considered necessary.

8. Transaction relating to Investment in IGL Genesis Technologies Limited

We draw attention to Note 11 to the accompanying financial results, which describes that M/s Genesis Gas Solutions Private Limited ("GGPL") has entered into a Share Purchase Agreement with Vikas Lifecare Limited ("VLL") for the transfer of its investment in IGL Genesis Technologies Limited ("IGTL"), pursuant to which the shares were transferred in dematerialized form in May 2025. However, as at the reporting date and the date of approval of these financial results, certain conditions precedent to the completion of the transaction remains pending.

As further explained in the said note, the transfer is subject to requisite approvals from the Board of Indraprastha Gas Limited and the Board of IGTL, in accordance with the terms of the Shareholders' cum Joint Venture Agreement, and pending such approvals,



the name of the shareholder as appearing in the register of members of IGTL continues to remain unchanged.

In view of the above, the transfer of shares has not been given effect in the books of account. The accounting treatment of the said investment will be determined upon completion of the transaction and receipt of the necessary approvals.

9. Tax Implications of Settlement Transaction

We draw attention to note 12 in the accompanying financial results, which describes that pursuant to the transaction involving contribution made by the Company towards acquisition of Ebix Inc. and subsequent settlement thereof, the Company has received 51% equity shares of Ebix UK in accordance with the Settlement Agreement dated 14 May 2025.

The Company is in the process of evaluating the tax implications arising from the aforesaid transaction, including the characterization of the transaction, its taxability under applicable laws, Pending completion of such evaluation and receipt of expert opinions, no tax impact, if any, has been recognized in the accompanying financial results.

Our conclusion is not modified in respect of above matters.

For KSMC & Associates
Chartered Accountants
FRN: 003565N



CA SACHIN SINGHAL
(Partner)
M. No: 505732
UDIN: 26505732CUXAGW1883

Place: New Delhi
Date: 21.04.2026

VIKAS LIFECARE LIMITED

CIN - L25111DL1995PLC073719

REGD OFF: VIKAS HOUSE,3,ARIHANT NAGAR ROHTAK ROAD,PUNJABI BAGH WEST,DELHI-110026 PH NO: 011-40450110 EMAIL - info@vikaslifecarelimited.com

UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER & NINE MONTHS ENDED 31ST DECEMBER, 2025

Sr. No.	Particulars	Three Months Ended			Nine Months Ended		Year Ended
		31-Dec-25 Unaudited	30-Sep-25 Unaudited	31-Dec-24 Unaudited	31-Dec-25 Unaudited**	31-Dec-24 Unaudited	31-Mar-25 Audited
1	Revenue from Operations						
a.	Revenue from Operations	9,653.77	14,097.78	11,198.90	32,620.74	33,390.71	46,357.62
2	Other Income	-14.45	40.98	(55.48)	13,328.38	534.95	2,632.65
3	Total Income (1+2)	9,639.32	14,138.76	11,143.42	45,949.12	33,925.66	48,990.27
4	EXPENSES :						
a.	Cost of Materials Consumed	821.39	292.15	10.19	1,137.92	530.51	559.34
b.	Purchases of Stock-in-Trade	8,154.26	13,606.02	11,249.33	30,419.18	32,485.79	44,641.67
c.	Change in inventory stock in trade	290.55	-79.72	(297.17)	170.51	(531.85)	(89.09)
d.	Employee Benefits Expense	53.84	53.72	61.99	159.95	166.67	223.46
e.	Finance Costs	199.33	105.61	131.74	412.47	280.35	390.70
f.	Depreciation and Amortisation Expense	148.07	147.90	142.12	441.34	444.86	652.47
g.	Other Expenses	1,848.13	469.02	395.31	2,768.35	820.10	2,966.96
	Total Expenses	11,515.56	14,594.71	11,693.49	35,509.71	34,196.42	49,345.51
5	Profit Before Exceptional Items and Tax (3-4)	(1,876.24)	(455.96)	(550.07)	10,439.41	(270.76)	(355.24)
6	Exceptional Items						
7	Profit/ (Loss) Before Tax (5-6)	(1,876.24)	(455.96)	(550.07)	10,439.41	(270.76)	(355.24)
8	Tax Expense/(Benefits):						
i.	Current Tax	-	-7.39	221.36	-	301.24	378.11
ii.	Deferred Tax	-403.83	-99.15	(254.97)	(502.98)	(254.97)	(507.69)
iii.	Previous Year Income Tax	-	-	-	-	-	-
	Total Tax Expense (i+ii+iii)	(403.83)	(106.54)	(33.61)	(502.98)	46.27	(129.58)
9	Net Profit/(Loss) from continuing operations (7-8)	(1,472.41)	(349.43)	(516.46)	10,942.39	(317.04)	(225.66)
10	Profit/(loss) from discontinued operations						
11	Tax expenses of discontinued operations						
12	Profit/(loss) from Discontinued operations (after tax) (10-11)						
13	Profit/(loss) for the period (9+12)	(1,472.41)	(349.43)	(516.46)	10,942.39	(317.04)	(225.66)
	Other Comprehensive Income :						
A.)	(i) Items that will not be reclassified to Profit and Loss	-12.05	-21.68	(12.85)	-22.08	563.27	500.38
	(ii) income tax relating to items that will not be reclassified to profit or loss	3.03	5.46	3.23		(141.76)	(125.93)
					5.56		
B)	(i) items that will be reclassified to profit and loss account	-0.36	0.73	4.29	1.46	3.22	3.89
	(ii) income tax relating to items that will be reclassified to profit or loss	0.09	-0.18	-1.08		(0.81)	(0.98)
					-0.37		
14	Total Other Comprehensive Income	(9.29)	(15.67)	(6.40)	(15.43)	423.92	377.35
15	Total comprehensive income (Comprising Profit (Loss) and Other Comprehensive Income for the period) (13+14)	(1,481.69)	(365.09)	(522.86)	10,926.96	106.88	151.69
16	Paid up Equity Share Capital (Face Value Rs.1 each)	18,598.36	18,598.36	18,598.36	18,598.36	18,598.36	18,598.36
17	Earning per Equity Share:						
	Equity shares of par value Rs 1 each						
	(EPS for three months ended periods are not annualised)						
	Basic	(0.08)	(0.02)	(0.03)	0.59	0.01	(0.01)
	Diluted	(0.08)	-0.02	(0.03)	0.59	0.01	(0.01)
	** Includes restated figures of Quarter ended June-2025						

For Vikas Lifecare Limited

Sundeep Kumar Dhawan
Managing director
DIN : 09508137

Place: New Delhi
Date 21 April, 2026

Information on Segment Reporting pursuant to Ind AS 108 - Operating Segments**Operating segments:**

Trading & Manufacturing Division -Agro
 Trading & Manufacturing Division -Polymers
 Trading Division -Infrastructure

Identification of segments:

The chief operational decision maker monitors the operating results of its business segments separately for the purpose of making decisions about resource allocation and performance assessment. Segment performance is evaluated based on profit and loss of the segment and is measured consistently with profit or loss in these financial Results. Operating segments have been identified on the basis of the nature of products and Services.

Segment revenue and results

The expenses and income which are not directly attributable to any business segment are shown as unallocable expenditure (net of unallocable income).

The measurement principles of segments are consistent with those used in preparation of these financial Results. There are no inter-segment transfers.

1. Revenue by Geographical Location

(Figures in Lakhs)

Particulars	Three months Ended			Nine months Ended		Year Ended
	For the period ended December 31st, 2025	For the period ended September 30th, 2025	For the period ended December 31st, 2024	For the period ended December 31st, 2025	For the period ended December 31st, 2024	For the period ended March 31st, 2025
Domestic	9,653.77	14,097.78	11,198.9	32,620.74	33,390.71	45,972.33
Export-	-	-	-	-	-	385.28
Nepal	-	-	-	-	-	-
Benin	-	-	-	-	-	-
Mauritius	-	-	-	-	-	-
Bangladesh	-	-	-	-	-	-
Ghana	-	-	-	-	-	385.28
UAE	-	-	-	-	-	-
China	-	-	-	-	-	-
Total	9,653.77	14,097.78	11,198.90	32,620.74	33,390.71	46,357.62

2. Revenue by nature of products

Particulars	For the period ended December 31st, 2025	For the period ended September 30th, 2025	For the period ended December 31st, 2024	For the period ended December 31st, 2025	For the period ended December 31st, 2024	For the period ended March 31st, 2025
(a) Real estate Division	-	-	-	-	-	-
(b) Trading & Manufacturing Division -Polymers	937.80	441.80	474.68	1,685.87	1,336.77	1,753.87
(c) Trading & Manufacturing Division -Agro	7,313.70	12,607.36	9,434.43	27,467.60	27,527.11	37,908.90
(d) Trading & Manufacturing Division -Infrastructure	1,402.27	1,048.62	1,289.79	3,467.27	4,526.83	6,694.85
Total	9,653.77	14,097.78	11,198.90	32,620.74	33,390.71	46,357.62

3. Segment Results before tax and interest

Particulars	For the period ended December 31st, 2025	For the period ended September 30th, 2025	For the period ended December 31st, 2024	For the period ended December 31st, 2025	For the period ended December 31st, 2024	For the period ended March 31st, 2025
(a) Real estate Division	-	-	-	-	-	-
(b) Trading & Manufacturing Division -Polymers	-9.86	20.50	24.81	37.77	190.88	32.61
(c) Trading & Manufacturing Division -Agro	378.75	228.70	171.57	777.79	617.97	1,091.50
(d) Trading & Manufacturing Division -Infrastructure	18.67	30.12	40.18	77.58	97.41	121.58
Sub Total	387.57	279.33	236.56	893.14	906.26	1,245.70
Less: Finance Cost	199.33	105.61	131.74	412.47	280.35	390.70
Add: Other Income	-14.45	68.17	-55.48	13,328.38	534.95	2,632.65
Less: Unallocated Expenses	2,050.04	697.82	599.41	3,369.64	1,431.62	3,842.90
Profit before tax	(1,876.26)	(455.95)	(550.06)	10,439.41	(270.76)	(355.24)
Less: Tax expenses	-403.83	-106.54	-33.61	-502.98	46.27	(129.58)
Net profit/(loss) for the Period	(1,472.41)	(349.41)	(516.46)	10,942.39	(317.04)	(225.66)

4. Major Customers

(a)	For the Quarter ending December 2025, the company does not have major customers as per IND-AS 108.
(b)	For the Quarter ended September 2025 Revenue from one customer of the Segment Trading & Manufacturing Division - Agro represented approximately Rs. 1,727.73 Lacs of the total revenue.
(c)	For the Quarter ended December 2024 Revenue from two customers of the Segment Trading & Manufacturing Division - Agro represented approximately Rs. 3,002.00 Lacs, and Rs. 1,869.46 Lacs of the total revenue.
(d)	For the Nine Months ending December 2025, the company does not have major customers as per IND-AS 108.
(e)	For the Nine Months ended December 2024 Revenue from two customers of the Segment Trading & Manufacturing Division - Agro represented approximately Rs. 4,478.15 Lacs, and Rs. 3,861.54 Lacs of the total revenue.
(f)	For the Year ended March 2025 Revenue from one customer of the Segment Trading & Manufacturing Division - Agro represented approximately Rs. 4980.92 Lacs of the total revenue.
(g)	Segment revenue and results include the respective amounts identifiable to each of the segments and amounts allocated on a reasonable basis.

For Vikas Lifecare Limited

Sundeep Kumar Dhawan
 Managing Director
 DIN:09508137

VIKAS LIFECARE LIMITED

CIN - L25111DL1995PLC073719

REGD OFF: VIKAS HOUSE,3,ARIHANT NAGAR ROHTAK ROAD,PUNJABI BAGH WEST,DELHI-110026 PH NO: 011-40450110 EMAIL - info@vikaslifecarelimited.com

Notes to unaudited standalone financial results for the Nine Month ended December 31, 2025

1 Summary of Profit before impact of Fair Value Changes through Profit and Loss Account related to Investments

Particulars	Nine Months Ended 31.12.2025	Year Ended 31.03.2025
	Unaudited	Audited
Profit Before Tax	10,439.41	(355.24)
Less: Reassessment gain/(loss) on account investments fair valued through FVTPL	(1,759.48)	(1,959.75)
Profit of the company excluding impact of Reassessment gain/(loss) on account investments fair valued through FVTPL	12,198.89	1,604.51

2 The standalone financial results of the company have been prepared in accordance with Ind AS prescribed under Section 133 of the Companies Act 2013 (the Act) read with the relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015.

3 The above unaudited Standalone financial results have been reviewed and recommended by the Audit Committee and approved by the Board of Directors at their meeting at the Registered office held on 21st April, 2026. The auditors have issued an unmodified review report on the financial results for the quarter and Half year ended 30th September, 2025.

4 In accordance with Ind AS, the company has recognised actuarial gains or losses on actuarial valuation of the Defined Benefit Obligation in "Other Comprehensive Income".

5 The results of the Company are also available for investors at www.vikaslifecarelimited.com, www.bseindia.com and www.nseindia.com

6 Investment in Unquoted shares/securities is subject to fair valuation and such investments has been kept at book value.

7 The previous year figures have been regrouped / reclassified, wherever necessary to confirm to the current year presentation.

8 Investor Complaints

Pending at the beginning of the quarter	-
Received during the quarter	-
Disposed off during the quarter	-
Remaining unresolved at the end of the quarter	-

9 During the previous year, Eraaya Lifespaces Limited (ELL/holding company) acquired the Ebix Inc and all its global subsidiaries through successful bids approved by the debtors and plan sponsor as part of the Chapter 11 proceedings under the supervision of Dallas Court at the United States (U.S.).

As part of a consortium led by ELL, Vikas Lifecare Limited (VLL) contributed ₹ 2,977.27 million (equivalent US\$ 34.83 million) towards the acquisition of Ebix Inc. Further, an addendum agreement dated August 16, 2024, provided that in case of non-repayment by ELL, VLL may receive 51% shares of Ebix International Holdings Limited (EIHL) (the step down subsidiary of the Company). Owing to non-repayment by January 31, 2025, VLL invoked the Arbitration Clause of the Agreement. During the quarter ended June 30, 2025, the arbitration proceedings were concluded through a settlement deed, and accordingly, 51% of equity shares of EIHL have been transferred to VLL and necessary adjustments have been made in the unaudited financial results (restated) for the quarter ended June 30, 2025.

Further, the relevant applications, seeking requisite orders and/or approvals including regulatory approvals, wherever applicable, are to be obtained by the company. Further, ELL and Ebix Inc have been accorded specified rights in relation to the management and operations of EIHL and its subsidiaries, including participation in key decision-making and the ability to influence relevant financial and operational policies of EIHL and its subsidiaries. Based on management's assessment and in accordance with the principles laid down in Ind AS 110 Consolidated Financial Statements, the Company (VLL) does not presently exercise control over Ebix UK and its subsidiaries. Accordingly, the investment has been accounted for as an associate using the equity method in accordance with Ind AS 28 Investments in Associates and Joint Ventures.

The management of the Company is undertaking a comprehensive review of applicable compliance requirements and is actively coordinating with legal and regulatory advisors to ensure compliances, if any, in an expedite manner, considering the cross-border nature of the transactions.

10 Related Party Transactions

During the half year ended September 30, 2025, the Company entered into certain related party transactions. As per the provisions of Regulation 23 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, prior approval of the Shareholder of the listed entity is required for material related party transactions. As at the date of approval of these Financial Results, shareholders' approval of the Company for such material related party transactions yet been obtained.

Further, the company is in the process of evaluating the regulatory compliance requirements and obtaining the necessary approvals, where applicable. Management is also reviewing the supporting documentation and underlying business rationale in respect of the aforesaid transactions and will take appropriate actions, including providing additional disclosures, if considered necessary.

11 Transaction relating to Investment in IGL Genesis Technologies Limited

M/s Genesis Gas Solutions Private Limited ("GGPL") has entered into a Share Purchase Agreement with Vikas Lifecare Limited ("VLL") for the transfer of its investment in IGL Genesis Technologies Limited ("IGTL"). Pursuant to the said agreement, the shares were transferred in dematerialized form in May 2025.

However, as at the reporting date and the date of approval of these financial results, certain conditions precedent to the completion of the transaction, as stipulated in the Share Purchase Agreement, remain pending.

Further, the said transfer is subject to requisite approvals from the Board of Indraprastha Gas Limited ("IGL") and the Board of IGTL, in accordance with the terms of the Shareholders' cum Joint Venture Agreement ("SHA") entered into between GGPL and IGL, which requires consent of the joint venture partner for such transfer. Pending receipt of these approvals, the name of the shareholder as appearing in the register of members of IGTL continues to remain unchanged.

In view of the above, the transfer of shares has not been given effect in the books of account. The accounting treatment of the said investment will be determined upon completion of the transaction and receipt of the necessary approvals.

The necessary steps are being undertaken to obtain the required approvals and that stakeholders will be duly informed upon receipt of the same.

12 Tax Implications of Settlement Transaction

Pursuant to the transaction involving contribution of US\$ 34.83 million made by company towards acquisition of Ebix Inc. and subsequent settlement of same in accordance with the Settlement Agreement dated 14 May 2025, the Company has received 51% equity shares of Ebix UK.

The Company is currently evaluating the tax implications arising from the aforesaid transaction, including, inter alia, the appropriate characterization of the transaction, its taxability under applicable provisions of the Income-tax Act, 1961.

Pending receipt of expert opinions from relevant tax and legal professionals, the Company has not recognized any tax impact, if applicable, in the accompanying financial results. Any tax liability or consequential financial impact arising from the outcome of such evaluation shall be appropriately accounted for in the financial statements for the financial year 2025-26, in accordance with the applicable accounting standards and prevailing tax laws.

13 **Restated notes to unaudited standalone financial results for the quarter ended June 30, 2025**

Note 1 of standalone unaudited financial results for the quarter ended June 30, 2025 should be read as below:

i **Original Note no. 1 of unaudited standalone financial results for the quarter ended June 30, 2025**

Particulars	Quarter Ended 30.06.2025	Year Ended 31.03.2025
	Unaudited	Audited
Profit before tax	-277.36	(355.24)
Less: Reameasurement gain/(loss)	-236.46	(1,959.75)
Profit of the company Excluding reameasurement gain and Losses	-40.89	1,604.51

ii **Restated Note 1 of standalone unaudited financial results for the quarter ended June 30, 2025**

Other Income includes profit or loss on reameasurment investment at fair value through profit and Loss Account. Summary of the same is depicted below:-

Particulars	Quarter Ended 30.06.2025	Year Ended 31.03.2025
	Unaudited	Audited
Profit before tax	12,771.62	(355.24)
Less: Reameasurement gain/(loss)	-236.46	(1,959.75)
Profit of the company Excluding reameasurement gain and Losses	13,008.08	1,604.51

iii **Reason for restatement**

Subsequent to the issuance of the previously reported financial results, additional information came to light indicating about transfer of shares of Ebix International Holding Limited (Ebix UK), a step down subsidiary of the Eraaya Lifespaces Limited to Vikas Lifecare Limited in pursuance of settlement deed, it was discovered that the same has not been accounted and disclosed in the financial results for the quarter ended June 30, 2025.

In accordance with the requirements of Ind AS 8 - Accounting Policies, Change in Accounting Estimates and Errors, such omission has been evaluated and the financial results have been restated to incorporate the necessary adjustments and disclosures and ensure appropriate effect and presentation in respect to such settlement.

iii **Impact of restatement**

Impact on Profit and Loss Account

Particulars	April to June 30, 2025 (Reported)	April to June 30, 2025 (Restated)	Change	Nature
Cost				
Other Expenses	442.77	424.02	-18.75	Change in Exchange Rate Fluctuation Gain/Loss
Provision for Income Tax	2.67	7.39	4.72	Income Tax Provision on gain/loss arises on settlement of transaction
Income				
Other Income	244.45	13,274.67	13,030.22	Recognition of gain arises on settlement vide transfer of investment of Ebix International Holding and Change in Exchange Rate Fluctuation Gain/Loss
Profit/ (Loss) for the period (After Tax)	-280.03	12,764.23	13,044.25	Resultant Change due to above changes in cost and income
EPS				
Basic	-0.01	0.69	0.70	Resultant Change due to above changes in cost and income
Diluted	-0.01	0.69	0.70	

Impact on Balance Sheet

Investment	Amount in Lakhs	Impact	Remarks
Investment in UK	42,841.35	Increase	Impact due to recognition of
Other Financial Assets	28,081.50	Decrease	Investment related to transfer of
Other Current Liab.	1,710.88	Increase	shares of Ebix International Holdings
Current Tax Liabilities (Net)	4.72	Increase	in pursuance of settlement deed

For Vikas Lifecare Limited

Sundeep Kumar Dhawan
Managing director
DIN : 09508137

Place: New Delhi
Date: 21-04-2026



Independent Auditor's Limited Review Report on the Quarterly and Nine months Unaudited Consolidated Financial Results of Vikas Lifecare Limited pursuant to the Regulations 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulation 2015, as amended Review Report

To the Board of Directors

Vikas Lifecare Limited

1. We have reviewed the accompanying statement of unaudited consolidated financial results of Vikas Lifecare Limited (the "Parent") and its subsidiaries (the parent and its subsidiaries together referred to as "the group") for the quarter and nine months ended 31st December 2025 being submitted by the Parent pursuant to requirements of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations).
2. This statement is the responsibility of the Parent's Management and has been approved by the Parent's Board of Directors, our responsibility is to express a conclusion on the statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
4. The statement includes results of the following entities:
 - a. Shashi Beriwal And Company Private Limited (subsidiary)
 - b. Genesis Gas Solutions Private Limited (subsidiary)
 - c. Vikash Lifecare Investment Management LLC (wholly Owned subsidiary)
 - d. Vikas Sports Venture Private Limited(wholly Owned subsidiary)
 - e. IGL Genesis Technologies Limited (step down Associate)
 - f. Ebix International Holdings Limited (EIHL) (Associate)

The Group holds 51% equity interest in Ebix International Holdings Limited; however, based on the contractual arrangements and governance structure, the Group exercises significant influence and does not have control over the said entity. Accordingly, the investment has been classified as an Associate and accounted for using the equity method in accordance with Ind AS 28. The said Associate has its own subsidiaries/associates, which are consolidated at the level of the Associate. The Group's share of profit/loss and net assets of the Associate includes the impact of such subsidiaries/associates. These subsidiaries/associates have not been separately consolidated in the Group's consolidated financial results.



5. Based on our review conducted as stated in paragraph 3 and based on consideration of Management's certified financial results referred to in Paragraph 11 below, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable principles laid down in the accounting standard 34 Interim Financial Reporting (IND AS 34) prescribed under Section 133 of the Companies Act' 2013 read with relevant rules issued there under and other accounting principles generally accepted in India has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

Emphasis of Matters

6. We draw attention to Note 9 to the accompanying financial results which describes that during the previous year, Eraaya Lifespaces Limited ("ELL") had acquired the Ebix Inc and its global subsidiaries pursuant to Chapter 11 proceedings under the supervision of the Dallas Court, U.S. As further detailed in the said note, Vikas Lifecare Limited ("VLL"), as part of the consortium led by ELL, had contributed INR 2,977.27 million (equivalent to US\$ 34.83 million) towards the acquisition of Ebix Inc. In terms of an addendum agreement dated August 16, 2024, VLL was entitled to receive 51% equity shares of Ebix International Holdings Limited ("EIHL"), a subsidiary of the Ebix Inc, in the event of non-repayment by ELL. Upon such non-repayment by January 31, 2025, VLL invoked the arbitration clause, and the matter was settled during the quarter ended June 30, 2025 through a settlement deed. Pursuant thereto, 51% equity shares of EIHL have been transferred to VLL. Further, the requisite approvals, including regulatory approvals, as may be applicable for the aforesaid transaction, are in the process of being obtained by the Company. The management has represented that it is undertaking a comprehensive review of compliance requirements across jurisdictions and is actively coordinating with legal and regulatory advisors to regularize such compliances, considering the cross-border nature of the transaction
7. **Restatement of unaudited standalone financial results for the quarter ended June 30, 2025**

We draw attention to Note 13 to the accompanying financial results, which describes that unaudited standalone financial result for the quarter ended June 30, have been restated to reflect additional facts that came to management's attention subsequent to the issuance of the previously reported financial results. These developments relate to the transfer of shares of Ebix International Holding Limited (Ebix UK), a step down subsidiary of the Eraaya Lifespaces Limited in pursuance of settlement deed. Accordingly, the previously reported figures and disclosure in financial results have been restated to appropriately incorporate the effect and presentation in respect to such settlement.

8. **Related Party Transactions**

We draw attention to Note 10 to the financial results which describes which describes that during the half year ended September 30, 2025, the Company entered into certain related party transactions. As stated in the said note, in terms of Regulation 23 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, prior approval of the shareholders is required



for material related party transactions; however, as at the date of approval of these financial results, such approval has not yet been obtained.

Further, the company is in the process of evaluating the regulatory compliance requirements and obtaining the necessary approvals, where applicable. Management is also reviewing the supporting documentation and underlying business rationale in respect of the aforesaid transactions and will take appropriate actions, including providing additional disclosures, if considered necessary.

9. Transaction relating to Investment in IGL Genesis Technologies Limited

We draw attention to Note 11 to the accompanying financial results, which describes that M/s Genesis Gas Solutions Private Limited ("GGPL") has entered into a Share Purchase Agreement with Vikas Lifecare Limited ("VLL") for the transfer of its investment in IGL Genesis Technologies Limited ("IGTL"), pursuant to which the shares were transferred in dematerialized form in May 2025. However, as at the reporting date and the date of approval of these financial results, certain conditions precedent to the completion of the transaction remains pending.

As further explained in the said note, the transfer is subject to requisite approvals from the Board of Indraprastha Gas Limited and the Board of IGTL, in accordance with the terms of the Shareholders' cum Joint Venture Agreement, and pending such approvals, the name of the shareholder as appearing in the register of members of IGTL continues to remain unchanged.

In view of the above, the transfer of shares has not been given effect in the books of account. The accounting treatment of the said investment will be determined upon completion of the transaction and receipt of the necessary approvals.

10. Tax Implications of Settlement Transaction

We draw attention to note 12 to the accompanying results, which describes that pursuant to the transaction involving contribution made by the Company towards acquisition of Ebix Inc. and subsequent settlement thereof, the Company has received 51% equity shares of Ebix UK in accordance with the Settlement Agreement dated 14 May 2025.

The Company is in the process of evaluating the tax implications arising from the aforesaid transaction, including the characterization of the transaction, its taxability under applicable laws, Pending completion of such evaluation and receipt of expert opinions, no tax impact, if any, has been recognized in the accompanying financial results.

Our conclusion is not modified in respect of above matters.

11. Other Matters

- i. One associate, namely Ebix International Holdings Limited (EIH), whose interim unaudited consolidated financial results reflect Group's share of loss after tax of Rs. 1304.51 Lakhs and Rs. 12716.97 Lakhs, other comprehensive income of Rs. (26.88) Lakhs and Rs. 35.89 Lakhs for the quarter ended 31st December 2025 and for the nine months ended 31st December 2025 as considered in the consolidated unaudited financial results is based on the basis of management certified financial information which has been provided to us.



KSMC & ASSOCIATES

Chartered Accountants

Though the financial information of the said associate has not been reviewed by us, it has been subjected to review by the other auditor as part of the review of the consolidated financial information of Ebix Inc. (which is holding company of EIH) whose report has been furnished to us by the Management. Accordingly, our conclusion on the consolidated unaudited financial results, in so far as it relates to the amounts and disclosures included in respect of the said associate, is solely based on the report of such other auditor and the procedures performed by us as stated in paragraph 3 above.

- ii. We have not reviewed the financial information of 3 subsidiaries and 1 step down associate included in the consolidated financial results, whose financial information reflects total revenue of Rs. 49.16 lakhs and Rs. 453.21 lakhs (before consolidation adjustments), loss after tax of Rs. 130.97 lakhs and Rs. 541.35 lakhs (before consolidation adjustments), other comprehensive income of Rs. NIL and Rs. (0.70 Lakhs) for the quarter and nine months ended on 31st December 2025 respectively. The financial information of these entities has been certified by the respective managements and furnished to us, and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these entities, is based solely on such financial information.
- iii. Further, the aforesaid figures include the share of loss of Rs. 173.76 lakhs and Rs. 431.97 lakhs pertaining to an associate of one of these subsidiaries for the quarter and nine months ended on 31 Dec 2025. The financial statements of this associate have been reviewed by another auditor, whose report has been furnished to us by the management. Our conclusion, insofar as it relates to the amounts and disclosures pertaining to the said associate, is based solely on the report of such other auditor.

Our conclusion is not modified in respect of above matters.

For KSMC & Associates
Chartered Accountants
FRN: 035565N



CA SACHIN SINGHAL
(Partner)

M. No.: 505732

UDIN: 26505732-WTWSN X7616

Place: New Delhi
Date: 21.04.2026

VIKAS LIFECARE LIMITED

CIN - L25111DL1995PLC073719

REGD OFF: VIKAS HOUSE,3,ARIHANT NAGAR ROHTAK ROAD,PUNJABI BAGH WEST,DELHI-110026 PH NO: 011-40450110 EMAIL - info@vikaslifecarelimited.com

UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER & NINE MONTHS ENDED 31st December, 2025

Sr. No	Particulars	Three Months Ended			Nine Months Ended		Year Ended
		31-Dec-25	30-Sep-25	31-Dec-24	31-Dec-25	31-Dec-24	31-Mar-25
		Unaudited	Audited	Unaudited	Unaudited**	Unaudited	Audited
1	Revenue from Operations						
a.	Revenue from Operations	9,702.93	14,132.66	11,784.91	33,073.95	34,481.78	48,002.24
2	Other Income	72.88	86.45	(72.42)	13,486.04	487.48	2,596.27
3	Total Income (1+2)	9,775.81	14,219.10	11,712.49	46,560.00	34,969.25	50,598.52
4	EXPENSES :						
a.	Cost of Materials Consumed	821.39	292.15	532.07	1,137.92	1,272.17	1,709.66
b.	Purchases of Stock-in-Trade	8,170.16	13,676.51	11,317.94	30,854.34	32,705.55	44,861.43
c.	Change in inventory of finished goods, work in progress and stock in trade	290.56	-105.16	-297.62	97.16	(532.73)	(72.00)
d.	Employee Benefits Expense	103.76	111.11	118.82	321.86	328.38	441.67
e.	Finance Costs	197.37	183.57	142.44	496.44	311.36	457.11
f.	Depreciation and Amortisation Expense	150.44	150.19	146.04	448.40	461.54	673.54
g.	Other Expenses	1,882.02	521.07	326.79	2,868.03	910.23	3,222.16
	Total Expenses	11,615.69	14,829.44	12,286.48	36,224.15	35,456.49	51,293.57
5	Profit Before Exceptional Items and Tax (3-4)	(1,839.89)	(610.34)	(573.99)	10,335.85	(487.24)	(695.06)
6	Exceptional Items	-	-	-	-	-	-
	Share in profit (Loss) in Associate Company	-1,478.28	-11,397.51	(106.90)	(13,148.94)	(275.82)	(591.87)
7	Profit/ (Loss) Before Tax (5-6)	(3,318.16)	(12,007.85)	(680.89)	(2,813.09)	(763.06)	(1,286.93)
8	Tax Expense/(Benefits):						
i.	Current Tax	13.31	-12.66	259.78	13.31	301.24	378.11
ii.	Deferred Tax	-403.83	-99.15	(254.97)	-502.98	(254.97)	(592.66)
iii.	Previous Year Income Tax	-	-	-	-	-	19.16
	Total Tax Expense (i+ii+iii)	(390.53)	(111.81)	4.81	(489.67)	46.27	(195.39)
9	Net Profit/(Loss) from continuing operations (7-8)	(2,927.64)	(11,896.04)	(685.69)	(2,323.41)	(809.33)	(1,091.54)
10	Profit/(loss) from discontinued operations						-
11	Tax expenses of discontinued operations						-
12	Profit/(loss) from Discontinued operations (after tax) (10-11)						
13	Profit/(loss) for the period (9+12)	(2,927.64)	(11,896.04)	(685.69)	(2,323.41)	(809.33)	(1,091.54)
	Other Comprehensive Income :						
A.)	(i) Items that will not be reclassified to Profit and Loss	-11.35	-22.38	(12.85)	-22.08	563.27	506.03
	(ii) income tax relating to items that will not be reclassified to profit or loss	3.03	5.46	3.23	5.56	(141.76)	(127.35)
B)	(i) items that will be reclassified to profit and loss account	-0.36	0.73	3.46	1.46	3.22	-
	(ii) income tax relating to items that will be reclassified to profit or loss	0.09	-0.18	(0.87)	-0.37	(0.81)	-
	Share of Other Comprehensive Income of associates	-26.88	54.67	-	35.89	-	-
14	Total Other Comprehensive Income	(35.47)	38.30	(7.03)	20.46	423.92	378.68
15	Total comprehensive income (Comprising Profit (Loss) and Other Comprehensive Income for the period) (13+14)	(2,963.10)	(11,857.75)	(692.72)	(2,302.96)	(385.41)	(712.86)
16	Profit for the period attributable to:						
	Shareholders of the Company	-2,920.95	-11,895.22	(681.16)	(2,316.59)	(771.74)	(1,061.39)
	Non-controlling interests	-6.69	-0.83	(4.54)	(6.83)	(37.59)	(30.14)
		(2,927.64)	(11,896.05)	(685.69)	(2,323.41)	(809.33)	(1,091.54)
17	Other comprehensive income for the period attributable to:						
	Shareholders of the Company	-35.47	38.30	(7.00)	20.46	423.92	378.04
	Non-controlling interests	-	-	(0.03)	-	-	0.06
		(35.47)	38.30	(7.03)	20.46	423.92	378.10
18	Total comprehensive income for the period attributable to:						
	Shareholders of the Company	-2,956.41	(11,856.93)	(688.15)	(2,296.13)	(347.82)	(683.36)
	Non-controlling interests	-6.69	(0.83)	(4.57)	(6.83)	(37.59)	(30.08)
		(2,963.10)	(11,857.75)	(692.72)	(2,302.96)	(385.41)	(713.44)
19	Paid up Equity Share Capital (Face Value Rs.1 each)	18,598.36	18,598.36	18,598.36	18,598.36	18,598.36	18,598.36
20	Earning per Equity Share:						
	Equity shares of par value Rs 1 each						
	Basic	-0.16	-0.64	-0.04	-0.12	-0.02	-0.06
	Diluted	-0.16	-0.64	-0.04	-0.12	-0.02	-0.04
	** Includes restated figures of Quarter ended June-2025						

VIKAS LIFECARE LIMITED

CIN: L25111DL1995PLC073719

NOTES FORMING PART OF THE CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER & NINE MONTHS ENDED 31ST DECEMBER, 2025

Information on Segment Reporting pursuant to Ind AS 108 - Operating Segments

Operating segments:

Trading & Manufacturing Division -Agro
Trading & Manufacturing Division -Polymers
Trading Division -Infrastructure
Trading Division- Gas Meter

Identification of segments:

The chief operational decision maker monitors the operating results of its business segments separately for the purpose of making decisions about resource allocation and performance assessment. Segment performance is evaluated based on profit and loss of the segment and is measured consistently with profit or loss in these financial Results. Operating segments have been identified on the basis of the nature of products and Services.

Segment revenue and results

The expenses and income which are not directly attributable to any business segment are shown as unallocable expenditure (net of unallocable income).

The measurement principles of segments are consistent with those used in preparation of these financial Results. There are no inter-segment transfers.

1.

Particulars	Three months Ended			Nine months Ended		Year Ended
	For the period ended December 31st, 2025	For the period ended September 30th, 2025	For the period ended December 31st, 2024	For the period ended December 31st, 2025	For the period ended December 31st, 2024	For the period ended March 31st, 2025
Domestic	9,702.93	14,132.66	11,784.91	33,073.95	34,481.78	47,616.95
Export-	-	-	-	-	-	385.28
Nepal	-	-	-	-	-	-
Benin	-	-	-	-	-	-
Mauritius	-	-	-	-	-	-
Bangladesh	-	-	-	-	-	-
Ghana	-	-	-	-	-	385.28
China	-	-	-	-	-	-
Total	9,702.93	14,132.66	11,784.91	33,073.95	34,481.78	48,002.24

2. Revenue by nature of products

Particulars	For the period ended December 31st, 2025	For the period ended September 30th, 2025	For the period ended December 31st, 2024	For the period ended December 31st, 2025	For the period ended December 31st, 2024	For the period ended March 31st, 2025
(a) Real estate Division	-	-	-	-	-	-
(b) Trading & Manufacturing Division -Polymers	937.80	441.80	474.68	1,685.87	1,336.77	1,753.87
(c) Trading & Manufacturing Division -Agro	7,313.70	12,607.36	9,951.62	27,467.60	28,283.22	37,908.90
(d) Trading & Manufacturing Division -Infrastructure	1,360.56	1,130.54	1,289.79	3,798.90	4,526.83	8,034.58
(e) Trading Division- Gas Meter	90.87	(47.04)	68.82	121.58	334.96	304.89
(f) Technical Consultancy Services	-	-	-	-	-	-
Total	9,702.93	14,132.65	11,784.91	33,073.95	34,481.78	48,002.24

3. Segment Results before tax and interest

Particulars	For the period ended December 31st, 2025	For the period ended September 30th, 2025	For the period ended December 31st, 2024	For the period ended December 31st, 2025	For the period ended December 31st, 2024	For the period ended March 31st, 2025
(a) Real estate Division	-	-	-	-	-	-
(b) Trading & Manufacturing Division -Polymers	(9.86)	20.50	24.81	37.77	190.88	32.61
(c) Trading & Manufacturing Division -Agro	378.75	228.70	167.18	777.79	632.42	1,091.50
(d) Trading & Manufacturing Division -Infrastructure	(38.94)	87.70	40.18	82.90	97.41	292.83
(e) Trading Division- Gas Meter	90.87	(67.75)	(106.55)	86.08	(159.75)	86.22
Sub Total	420.82	269.16	125.62	984.54	760.96	1,503.16
Less: Finance Cost	197.37	183.57	142.44	496.44	311.36	457.11
Add: Other Income	72.88	59.26	(72.42)	13,486.04	487.48	2,596.27
Less: Unallocated Expenses	3,614.49	12,152.70	591.66	16,787.23	1,700.14	4,929.26
Profit before tax	-3,318.16	-12,007.85	-680.89	-2,813.09	-763.06	-1,286.93
Less: Tax expenses	(390.53)	(111.81)	4.80	-489.67	46.27	(195.39)
Net profit/ (loss) for the Period	-2,927.64	-11,896.04	-685.69	-2,323.41	-809.33	-1,091.54

4. Major Customers

(a)	For the Quarter ending December 2025, the company does not have major customers as per IND-AS 108.
(b)	For the Quarter ended September 2025 Revenue from one customer of the Segment Trading & Manufacturing Division - Agro represented approximately Rs. 1,727.73 Lacs of the total revenue.
(c)	For the Quarter ended December 2024 Revenue from two customers of the Segment Trading & Manufacturing Division - Agro represented approximately Rs. 3,002.00 Lacs, and Rs. 1,869.46 Lacs of the total revenue.
(d)	For the Nine Months ending December 2025, the company does not have major customers as per IND-AS 108.
(e)	For the Nine Months ended December 2024 Revenue from two customers of the Segment Trading & Manufacturing Division - Agro represented approximately Rs. 4,478.15 Lacs, and Rs. 3,861.54 Lacs of the total revenue.
(f)	For the Year ended March 2025 Revenue from one customer of the Segment Trading & Manufacturing Division - Agro represented approximately Rs. 4980.92 Lacs of the total revenue.
(g)	Segment revenue and results include the respective amounts identifiable to each of the segments and amounts allocated on a reasonable basis.

For Vikas Lifecare Limited

Sundeep Kumar Dhawan
Managing Director
DIN:09508137

VIKAS LIFECARE LIMITED

CIN - L25111DL1995PLC073719

REGD OFF: VIKAS HOUSE,3,ARIHANT NAGAR ROHTAK ROAD,PUNJABI BAGH WEST,DELHI-110026 PH NO: 011-40450110 EMAIL - info@vikaslifecarelimited.com

Notes to unaudited consolidated financial results for the Nine Month ended December 31, 2025

1 Summary of Profit before impact of Fair Value Changes through Profit and Loss Account related to Investments

Particulars	Nine Months Ended 31.12.2025	Year Ended 31.03.2025
	Unaudited	Audited
Profit Before Tax	(2,813.09)	(1,286.93)
Less: Reameasurement gain/(loss) on account investments fair valued through FVTPL	(1,759.48)	(1,959.75)
Profit of the company excluding impact of Reameasurement gain/(loss) on account investments fair valued through	-1,053.60	672.82

2 The consolidated financial results of the company have been prepared in accordance with Ind AS prescribed under Section 133 of the Companies Act 2013 (the Act) read with the relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015.

3 The above unaudited consolidated financial results have been reviewed and recommended by the Audit Committee and approved by the Board of Directors at their meeting at the Registered office held on 21 April, 2026. The auditors have issued an unmodified review report on the financial results for the quarter and Half year ended 30th September, 2025.

4 In accordance with Ind AS, the company has recognised actuarial gains or losses on actuarial valuation of the Defined Benefit Obligation in "Other Comprehensive Income".

5 The results of the Company are also available for investors at www.vikaslifecarelimited.com, www.bseindia.com and www.nseindia.com

6 Investment in Unquoted shares/securities is subject to fair valuation and such investments has been kept at book value.

7 The previous year figures have been regrouped / reclassified, wherever necessary to confirm to the current year presentation.

8 Investor Complaints

Pending at the beginning of the quarter	-
Received during the quarter	-
Disposed off during the quarter	-
Remaining unresolved at the end of the quarter	-

9 During the previous year, Eraaya Lifespaces Limited (ELL/holding company) acquired the Ebix Inc and all its global subsidiaries through successful bids approved by the debtors and plan sponsor as part of the Chapter 11 proceedings under the supervision of Dallas Court at the United States (U.S.).

As part of a consortium led by ELL, Vikas Lifecare Limited (VLL) contributed ₹ 2,977.27 million (equivalent US\$ 34.83 million) towards the acquisition of Ebix Inc. Further, an addendum agreement dated August 16, 2024, provided that in case of non-repayment by ELL, VLL may receive 51% shares of Ebix International Holdings Limited (EIHL) (the step down subsidiary of the Company). Owing to non-repayment by January 31, 2025, VLL invoked the Arbitration Clause of the Agreement.

During the quarter ended June 30, 2025, the arbitration proceedings were concluded through a settlement deed, and accordingly, 51% of equity shares of EIHL have been transferred to VLL and necessary adjustments have been made in the unaudited financial results (restated) for the quarter ended June 30, 2025.

Further, the relevant applications, seeking requisite orders and/or approvals including regulatory approvals, wherever applicable, are to be obtained by the company. Further, ELL and Ebix Inc have been accorded specified rights in relation to the management and operations of EIHL and its subsidiaries, including participation in key decision-making and the ability to influence relevant financial and operational policies of EIHL and its subsidiaries. Based on management's assessment and in accordance with the principles laid down in Ind AS 110 Consolidated Financial Statements, the Company (VLL) does not presently exercise control over Ebix UK and its subsidiaries. Accordingly, the investment has been accounted for as an associate using the equity method in accordance with Ind AS 28 Investments in Associates and Joint Ventures.

The management of the Company is undertaking a comprehensive review of applicable compliance requirements and is actively coordinating with legal and regulatory advisors to ensure compliances, if any, in an expedite manner, considering the cross-border nature of the transactions.

10 Related Party Transactions

During the half year ended September 30, 2025, the Company entered into certain related party transactions. As per the provisions of Regulation 23 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, prior approval of the Shareholder of the listed entity is required for material related party transactions. As at the date of approval of these Financial Results, shareholders' approval of the Company for such material related party transactions yet been obtained.

Further, the company is in the process of evaluating the regulatory compliance requirements and obtaining the necessary approvals, where applicable. Management is also reviewing the supporting documentation and underlying business rationale in respect of the aforesaid transactions and will take appropriate actions, including providing additional disclosures, if considered necessary.

11 Transaction relating to Investment in IGL Genesis Technologies Limited

M/s Genesis Gas Solutions Private Limited ("GGPL") has entered into a Share Purchase Agreement with Vikas Lifecare Limited ("VLL") for the transfer of its investment in IGL Genesis Technologies Limited ("IGTL"). Pursuant to the said agreement, the shares were transferred in dematerialized form in May 2025.

However, as at the reporting date and the date of approval of these financial results, certain conditions precedent to the completion of the transaction, as stipulated in the Share Purchase Agreement, remain pending.

Further, the said transfer is subject to requisite approvals from the Board of Indraprastha Gas Limited ("IGL") and the Board of IGTL, in accordance with the terms of the Shareholders' cum Joint Venture Agreement ("SHA") entered into between GGPL and IGL, which requires consent of the joint venture partner for such transfer. Pending receipt of these approvals, the name of the shareholder as appearing in the register of members of IGTL continues to remain unchanged.

In view of the above, the transfer of shares has not been given effect in the books of account. The accounting treatment of the said investment will be determined upon completion of the transaction and receipt of the necessary approvals.

The necessary steps are being undertaken to obtain the required approvals and that stakeholders will be duly informed upon receipt of the same.

12 Tax Implications of Settlement Transaction

Pursuant to the transaction involving contribution of US\$ 34.83 million made by company towards acquisition of Ebix Inc. and subsequent settlement of same in accordance with the Settlement Agreement dated 14 May 2025, the Company has received 51% equity shares of Ebix UK.

The Company is currently evaluating the tax implications arising from the aforesaid transaction, including, inter alia, the appropriate characterization of the transaction, its taxability under applicable provisions of the Income tax Act, 1961.

Pending receipt of expert opinions from relevant tax and legal professionals, the Company has not recognized any tax impact, if applicable, in the accompanying financial results. Any tax liability or consequential financial impact arising from the outcome of such evaluation shall be appropriately accounted for in the financial statements for the financial year 2025-26, in accordance with the applicable accounting standards and prevailing tax laws.

13 Restated notes to unaudited consolidated financial results for the quarter ended June 30, 2025

Note 1 of consolidated unaudited financial results for the quarter ended June 30, 2025 should be read as below:

i Original Note no. 1 of unaudited consolidated financial results for the quarter ended June 30, 2025

Particulars	Quarter Ended 30.06.2025	Year Ended 31.03.2025
	Unaudited	Audited
Profit before tax	-387.33	(1,286.93)
Less: Reameasurement gain/(loss)	-236.46	(1,959.75)
Profit of the company Excluding remeasurement	-150.87	672.82

i Restated Note 1 of consolidated unaudited financial results for the quarter ended June 30, 2025

Other Income includes profit or loss on remeasurement investment at fair value through profit and Loss Account, Summary of the same is depicted below:-

Particulars	Quarter Ended 30.06.2025	Year Ended 31.03.2025
	Unaudited	Audited
Profit before tax	12,512.93	(1,286.93)
Less: Reameasurement gain/(loss)	-236.46	(1,959.75)
Profit of the company Excluding remeasurement	12,749.39	672.82

ii Reason for restatement

Subsequent to the issuance of the previously reported financial results, additional information came to light indicating about transfer of shares of Ebix International Holding Limited (Ebix UK), a step down subsidiary of the Eraaya Lifespaces Limited to Vikas Lifecare Limited in pursuance of settlement deed, it was discovered that the same has not been accounted and disclosed in the financial results for the quarter ended June 30, 2025.

In accordance with the requirements of Ind AS 8 - Accounting Policies, Change in Accounting Estimates and Errors, such omission has been evaluated and the financial results have been restated to incorporate the necessary adjustments and disclosures and ensure appropriate effect and presentation in respect to such settlement.

iii Impact of restatement

Impact on Profit and Loss Account				
Particulars	April to June 30, 2025 (Reported)	April to June 30, 2025 (Restated)	Change	Nature
Cost				
Other Expenses	483.69	464.94	-18.75	Change in Exchange Rate Fluctuation Gain/Loss
Provision for Income Tax	7.95	12.66	4.72	Income Tax Provision on gain/loss arises on settlement of transaction
Income				
Other Income				Recognition of gain arises on settlement vide transfer of investment of Ebix International Holding and Change in Exchange Rate Fluctuation Gain/Loss
Share in profit (Loss) in Associate Company	-124.45	-273.15	-148.70	
Profit/ (Loss) for the period (After Tax)				Resultant Change due to above changes in cost and income
Other Comprehensive Income	-395.27	12,500.27	12,895.54	
Profit for the period attributable to:	9.53	17.63	8.10	
Shareholders of the Company	-395.97	12,499.59	12,895.56	Resultant Change due to above changes in cost and income
Other comprehensive income for the period attributable to:				
Shareholders of the Company	9.53	17.63	8.10	
EPS				
Basic	-0.02	0.67	0.69	
Diluted	-0.02	0.67	0.69	

Impact on Balance Sheet				
Investment	Amount in Lakhs	Impact	Remarks	
Investment in UK	42,931.91	Increase	Impact due to recognition of Investment related to transfer of shares of Ebix International Holdings in pursuance of settlement deed	
Other Equity-FCTR Reserve	231.16	Increase		
Other Financial Assets	28,081.50	Decrease		
Other Current Liab.	1,710.88	Increase		
Current Tax Liabilities (Net)	4.72	Increase		

For Vikas Lifecare Limited

Sundeep Kumar Dhawan
Managing director
DIN : 09508137

Place: New Delhi
Date: 21-04-2026